EP3062709A2 - Système de tension à multiples points d'ancrage - Google Patents

Système de tension à multiples points d'ancrage

Info

Publication number
EP3062709A2
EP3062709A2 EP14802711.3A EP14802711A EP3062709A2 EP 3062709 A2 EP3062709 A2 EP 3062709A2 EP 14802711 A EP14802711 A EP 14802711A EP 3062709 A2 EP3062709 A2 EP 3062709A2
Authority
EP
European Patent Office
Prior art keywords
tissue anchor
pulley
tether
tissue
implanting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14802711.3A
Other languages
German (de)
English (en)
Inventor
Michael Gilmore
Idan Tobis
Charlotte MURPHY
Kevin Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4Tech Inc
Original Assignee
4Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Tech Inc filed Critical 4Tech Inc
Publication of EP3062709A2 publication Critical patent/EP3062709A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0487—Suture clamps, clips or locks, e.g. for replacing suture knots; Instruments for applying or removing suture clamps, clips or locks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0466—Suture bridges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0409—Instruments for applying suture anchors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0414—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors having a suture-receiving opening, e.g. lateral opening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/044—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors with a threaded shaft, e.g. screws
    • A61B2017/0441—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors with a threaded shaft, e.g. screws the shaft being a rigid coil or spiral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0464—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors for soft tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B2017/0496—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials for tensioning sutures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478—Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A61F2/2487—Devices within the heart chamber, e.g. splints

Definitions

  • Some applications of the present invention relate in general to valve repair. More specifically, some applications of the present invention relate to repair of an atrioventricular valve of a patient.
  • Functional tricuspid regurgitation is governed by several pathophysiologic abnormalities such as tricuspid valve annular dilatation, annular shape abnormality, pulmonary hypertension, left or right ventricle dysfunction, right ventricle geometry, and leaflet tethering.
  • pathophysiologic abnormalities such as tricuspid valve annular dilatation, annular shape abnormality, pulmonary hypertension, left or right ventricle dysfunction, right ventricle geometry, and leaflet tethering.
  • Treatment options for FTR are primarily surgical.
  • the current prevalence of moderate-to-severe tricuspid regurgitation is estimated to ⁇ be 1.6 million in the United States. Of these, only 8,000 patients undergo tricuspid valve surgeries annually, most of them in conjunction with left heart valve surgeries.
  • a valve-tensioning implant for repairing an atrioventricular valve of a subject by applying tension using multiple anchor points.
  • the valve-tensioning implant comprises at least first, second, and third tissue anchors, and a pulley system.
  • the pulley system comprises a pulley and a first tether, which is connected to the second and the third tissue anchors, and is moveable through the pulley.
  • the pulley system is arranged so as to achieve a desired distribution and transfer of forces between the three or more tissue anchors.
  • the pulley is arranged such that the maximum load applied when implanting the last of the tissue anchors (e.g., the third tissue anchor) is transferred between the other two tissue anchors that were earlier implanted (e.g., the first and the second tissue anchors).
  • the load transferred to the first and the second tissue anchors approximates the first and the second tissue anchors.
  • two of the tissue anchors may be helical tissue anchors that are implanted around the annulus of the right atrium using mechanical purchase, and the other tissue anchor may comprise an intraluminal stent that is configured to be implanted in the superior vena cava, the inferior vena cava, or the coronary sinus and provide anchorage using friction only.
  • the anchors and pulley system are arranged to apply relatively less force on the stent anchor than on one or both of the other helical tissue anchors.
  • one of the tissue anchors may be located in a region of tissue which is thicker or stronger than the implantation sites at which the other tissue anchors are implanted.
  • the pulley system may be arranged to align force vectors along a preferable direction which causes constriction of the tricuspid valve in a desired manner.
  • Repairing the atrioventricular valve typically facilitates reduction of atrioventricular valve regurgitation by altering the geometry of the atrioventricular valve and/or by altering the geometry of the wall of the right or left atrium of the heart.
  • implantation of the valve-tensioning implant achieves bicuspidization of the tricuspid valve.
  • the anterior leaflet and the septal leaflet are typically drawn together to enhance coaptation.
  • a multiple- anchor delivery tool for sequentially delivering and implanting two or more helical tissue anchors of an implant.
  • the implant comprises at least first and second helical tissue anchors, which comprise first and second heads, respectively, which comprise first and second tether interfaces.
  • the implant also comprises a tether, which is connected to first tether interface, and coupled to second tether interface (optionally slidably coupled to second tether interface, such that the tether is moveable through the second tether interface).
  • the multiple-anchor delivery tool comprises a catheter shaft having proximal and distal ends. The first and the second tissue anchors are initially removably positioned in the catheter shaft at first and second longitudinal locations, respectively.
  • the first longitudinal location is more distal than the second longitudinal location.
  • the tissue anchors are initially positioned in the desired sequence of deployment in the tube, with the first anchor to be deployed positioned more distally than the subsequent anchor(s) to be deployed.
  • the tissue anchors are interconnected by the tether.
  • the multiple-anchor delivery tool further comprises first and second torque cables, which (a) are removably coupled to the first and second heads, respectively, (b) extend within the tube proximally from the first and second heads, respectively, and (c) transmit torque when rotated, for rotating tissue-coupling elements of the anchors, respectively, into tissue.
  • the torque cables additionally transmit axial force, to enable pushing of the tissue-coupling elements into the tissue as they are rotated.
  • a portion of the first torque cable is initially removably positioned alongside the second tissue anchor in the tube.
  • the first tissue anchor is implanted into tissue of the subject by rotating the first torque cable.
  • the first torque cable is then decoupled from the first tissue anchor.
  • the second tissue anchor is distally advanced in the tube.
  • the second tissue anchor is implanted into tissue of the subject by rotating the second torque cable.
  • the second torque cable is then decoupled from the second tissue anchor.
  • apparatus including a valve-tensioning implant, which includes:
  • a first venous tissue anchor which is configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus;
  • Atrial tissue anchors which consist of second and third atrial tissue anchors.
  • a pulley system which includes:
  • a pulley which is connected to the second atrial tissue anchor; and a tether, which (a) is connected to the first venous tissue anchor and the third atrial tissue anchor, (b) is moveable through the pulley, and (c) has a length, measured between the first venous and the third atrial tissue anchors, of at least 30 mm.
  • the pulley includes a loop, and the tether is slidably moveable through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop includes a closed loop.
  • the pulley includes a ring, and the tether is slidably moveable through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the first venous tissue anchor includes an intraluminal stent.
  • the second and the third atrial tissue anchors include respective helical tissue-coupling elements.
  • the tether may be a first tether
  • the length may be a first length
  • the pulley system may further include a second tether which (a) is connected to the pulley and the second atrial tissue anchor, so as to connect the pulley to the second atrial tissue anchor, and (b) has a second length, measured between the second atrial tissue anchor and the pulley, of at least 3 mm.
  • the second length equals at least 10% of the first length.
  • the first length is between 30 and 120 mm
  • the second length is between 5 and 8 mm.
  • the second atrial tissue anchor may include (a) a tissue-coupling element, and (b) a head, and the pulley may be connected to the head such that, when the pulley is fully extended away from the head, a distance between (a) a site on the pulley farthest from the head and (b) a site on the head closest to the pulley, is at least 3 mm.
  • the head is rigid.
  • the head includes a tether interface that is rotatable with respect to the tissue- coupling element.
  • the second atrial tissue anchor may include (a) a tissue-coupling element, and (b) a head, which includes the pulley.
  • the head includes an interface, which (a) includes the pulley and (b) is rotatable with respect to the tissue-coupling element.
  • the pulley includes an eyelet.
  • the pulley includes a roller.
  • the pulley includes a flexible longitudinal member that is connected to the head at two points along the flexible longitudinal member, so as to define a loop longitudinally between the two points.
  • the second tissue-coupling element is helical.
  • the third atrial tissue anchor includes a helical tissue-coupling element.
  • the apparatus may further include a delivery system, configured to deliver and enable implantation of the valve-tensioning implant, and the delivery system may include at least one catheter shaft.
  • apparatus including a valve-tensioning implant which includes:
  • a first venous tissue anchor which is configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus;
  • tissue anchors which consist of second and third atrial tissue anchors.
  • a pulley system which includes:
  • a pulley which is connected to the first venous tissue anchor; a first tether, which (a) is connected to the second and the third atrial tissue anchors, (b) is moveable through the pulley, and (c) has a first length, measured between the second and the third atrial tissue anchors, of at least 10 mm; and
  • a second tether which (a) is connected to the first venous tissue anchor and to the pulley, and (b) has a second length, measured between the first venous tissue anchor and the pulley, of at least 30 mm.
  • the pulley includes a loop, and the second tether is slidably moveable through the loop.
  • a coefficient of kinetic friction between the second tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop includes a closed loop.
  • the pulley includes a ring, and the second tether is slidably moveable through the ring.
  • a coefficient of kinetic friction between the second tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the first venous tissue anchor includes an intraluminal stent.
  • the second and the third atrial tissue anchors include respective helical tissue-coupling elements.
  • the second length equals at least the first length.
  • the first length is between 20 and 50 mm.
  • the second length is between 30 and 80 mm.
  • the apparatus may further include a delivery system, configured to deliver and enable implantation of the valve-tensioning implant, and the delivery system may include at least one catheter shaft.
  • apparatus including a valve-tensioning implant, which includes:
  • first, second, and third tissue anchors first, second, and third tissue anchors
  • a pulley system which includes:
  • a first tether which (a) is connected to the second and the third tissue anchors, (b) is moveable through the pulley, and (c) has a first length, measured between the second and the third tissue anchors, of at least 15 mm;
  • a second tether which (a) is connected to the first tissue anchor and to the pulley, and (b) has a second length, measured between the first tissue anchor and the pulley, of at least 15 mm.
  • the apparatus includes exactly three tissue anchors, which consist of the first, the second, and the third tissue anchors, and no other tissue anchors.
  • the pulley includes a loop, and the first tether is slidably moveable through the loop.
  • a coefficient of kinetic friction between the first tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop includes a closed loop.
  • the pulley includes a ring, and the first tether is slidably moveable through the ring.
  • a coefficient of kinetic friction between the first tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the second length equals at least 80% of the first length.
  • the first length is between 15 and 30 mm.
  • the second length is between 25 and 80 mm.
  • the second length equals at least 15% of the first length.
  • the first length is between 15 and 140 mm.
  • the first length is between 30 and 120 mm.
  • the third tissue anchor is configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the first anchor may be configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the first tissue anchor includes an intraluminal stent.
  • the second and third tissue anchors include respective helical tissue-coupling elements.
  • the third tissue anchor may include an intraluminal stent.
  • the first and the second tissue anchors include respective helical tissue-coupling elements.
  • the apparatus may further include a delivery system, configured to deliver and enable implantation of the valve-tensioning implant, and the delivery system may include at least one catheter shaft.
  • apparatus including a valve-tensioning implant, which includes:
  • a first tissue anchor which includes (a) a tissue-coupling element, and (b) a head; second and third tissue anchors; and
  • a pulley system which includes:
  • a pulley which is connected to the head of the first tissue anchor, such that, when the pulley is fully extended away from the head, a distance between (a) a site on the pulley farthest from the head and (b) a site on the head closest to the pulley, is at least 5 mm;
  • a tether which (a) is connected to the second and the third tissue anchors, (b) is moveable through the pulley, and (c) has a length, measured between the second and the third tissue anchors, of at least 15 mm.
  • the head is rigid.
  • the interface between the head of the tissue anchor and tether is rotatable with respect to the tissue-coupling element.
  • the pulley includes a loop, and the tether is slidably moveable through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop includes a closed loop.
  • the pulley includes a ring, and the tether is slidably moveable through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the third tissue anchor is configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the third tissue anchor includes an intraluminal stent.
  • the tissue-coupling element of the first tissue anchor includes a first helical tissue-coupling element
  • the second tissue anchor includes a second helical tissue-coupling element.
  • the distance equals at least 10% of the length.
  • the length is between 30 and 200 mm.
  • the distance is between 15 and 50 mm.
  • the apparatus may further include a delivery system, configured to deliver and enable implantation of the valve-tensioning implant, and the delivery system may include at least one catheter shaft.
  • apparatus including a valve-tensioning implant, which includes:
  • a first venous tissue anchor which is configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava and an inferior vena cava; a second atrial tissue anchor;
  • a third venous tissue anchor which is configured to be implanted in a coronary sinus
  • a pulley system which includes:
  • the pulley includes a loop, and the tether is slidably moveable through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop includes a closed loop.
  • the pulley includes a ring, and the tether is slidably moveable through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the first and the second venous tissue anchor includes first and second intraluminal stents, respectively.
  • a greatest outer diameter of the second intraluminal stent is no more than 80% of a greatest outer diameter of the first intraluminal stent, when the first and the second stents are unconstrained and fully radially expanded.
  • the second atrial tissue anchor includes a helical tissue-coupling element.
  • the tether may be a first tether
  • the length may be a first length
  • the pulley system may further include a second tether, which (a) is connected to the pulley and the second atrial tissue anchor, so as to connect the pulley to the second atrial tissue anchor, and (b) has a second length, measured between the second atrial tissue anchor and the pulley, of at least 3 mm.
  • the second length equals at least 10% of the first length.
  • the first length is between 30 and 80 mm.
  • the second length is between 5 and 8 mm.
  • the second atrial tissue anchor may include (a) a tissue-coupling element, and (b) a head, and the pulley may be connected to the head such that, when the pulley is fully extended away from the head, a distance between (a) a site on the pulley farthest from the head and (b) a site on the head closest to the pulley, is at least 3 mm.
  • the head is rigid.
  • the head includes an interface that is rotatable with respect to the tissue- coupling element.
  • the second atrial tissue anchor may include (a) a tissue-coupling element, and (b) a head, which includes the pulley.
  • the head includes an interface, which (a) includes the pulley and (b) is rotatable with respect to the tissue-coupling element.
  • the pulley includes an eyelet.
  • the pulley includes a roller.
  • the pulley includes a flexible longitudinal member that is connected to the head at two points along the flexible longitudinal member, so as to define a loop longitudinally between the two points.
  • the tissue-coupling element is helical.
  • the apparatus may further include a delivery system, configured to deliver and enable implantation of the valve-tensioning implant, and the delivery system may include at least one catheter shaft.
  • apparatus including:
  • an implant which includes:
  • first and second tissue anchors which include (a) first and second helical tissue-coupling elements, respectively, and (b) first and second heads, respectively, which include first and second tether interfaces;
  • a tether which is connected to the first tether interface, and coupled to the second tether interface;
  • a multiple-anchor delivery tool which includes:
  • first and the second tissue anchors are removably positioned in the catheter shaft at first and second longitudinal locations, respectively, the first longitudinal location more distal than the second longitudinal location;
  • first and second torque cables which (a) are removably coupled to the first and the second heads, respectively, (b) extend within the catheter shaft proximally from the first and the second heads, respectively, and (c) transmit torque when rotated, wherein a portion of the first torque cable is removably positioned alongside the second tissue anchor in the catheter shaft.
  • the implant further includes a third tissue anchor, which includes (a) a third helical tissue-coupling elements and (b) a third head, which includes a third tether interface, the tether,- which is coupled to the third tether interface,
  • the third tissue anchor is removably positioned in the catheter shaft at a third longitudinal location that is more proximal than the second longitudinal location
  • the multiple-anchor delivery tool further includes a third torque cable, which (a) is removably coupled to the third head, (b) extends within the catheter shaft proximally from the third head, and (c) transmits torque when rotated, wherein a portion of the second torque cable is removably positioned alongside the third tissue anchor in the catheter shaft.
  • the first tether interface is rotatable with respect to the first tissue-coupling element.
  • the first torque cable may be shaped so as to define a lumen therethrough, and the multiple-anchor delivery tool may further include a shaft, which removably passes through the lumen.
  • the head is shaped so as to define a proximal coupling element
  • the head including the proximal coupling element, is shaped so as to define a first longitudinal channel at least partially therethrough, which channel is coaxial with the head,
  • a distal end of the first torque cable includes a distal coupling element, which is shaped so as to define a second longitudinal channel therethrough, which channel is coaxial with the lumen of the first torque cable,
  • proximal and the distal coupling elements are shaped so as to define corresponding interlocking surfaces
  • the shaft when disposed through the first and the second channels, prevents decoupling of the distal coupling element from the proximal coupling element.
  • the shaft is shaped so as to define a sharp distal tip.
  • a first venous tissue anchor in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus, exactly two atrial tissue anchors, which consist of second and third atrial tissue anchors, at respective different atrial sites, each of which sites is selected from the group of sites consisting of: an annulus of a tricuspid valve, and a wall of a right atrium of a heart above the annulus of the tricuspid valve, and a pulley system, which includes (a) a pulley, which is connected to the second atrial tissue anchor, and (b) a tether, which (i) is connected to the first venous tissue anchor and the third atrial tissue anchor, (ii) is moveable through the pulley, and (iii) has a length, measured between the first venous and the third atrial tissue anchors, of at least 30 mm; and
  • the pulley includes a loop, and tensioning the tether includes sliding the tether through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop is a closed loop.
  • the pulley includes a ring, and tensioning the tether includes sliding the tether through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel
  • tensioning the tether includes rotating the wheel by moving the tether through the pulley.
  • the first venous tissue anchor includes an intraluminal stent, and implanting the first venous tissue anchor includes expanding the stent in the selected vein.
  • the second and the third atrial tissue anchors include respective helical tissue-coupling elements, and implanting the second and the third atrial tissue anchors includes rotating the helical tissue-coupling elements into tissue at the sites, respectively.
  • implanting the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system includes positioning the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system such that two longitudinal portions of the tether adjacent to and on opposite sides of the pulley define an angle therebetween of between 40 and 85 degrees.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the inferior vena cava.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor in the coronary sinus.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoposterior commissure of the tricuspid valve.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the superior vena cava.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor in the coronary sinus.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the coronary sinus.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve; and implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • the tether is a first tether; the length is a first length; the pulley system further includes a second tether, which (a) is connected to the pulley and the second atrial tissue anchor, so as to connect the pulley to the second atrial tissue anchor, and (b) has a second length, measured between the second atrial tissue anchor and the pulley, of at least 3 mm; and implanting the pulley system further includes implanting the second tether.
  • the second atrial tissue anchor includes (a) a tissue- coupling element, and (b) a head; the pulley is connected to the head; and tensioning the tether includes fully extending the pulley away from the head, such that a distance between (a) a site on the pulley farthest from the head and (b) a site on the head closest to the pulley, is at least 3 mm.
  • the head is rigid.
  • the head includes a tether interface that is rotatable with respect to the tissue-coupling element.
  • implanting the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system includes positioning the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system such that two longitudinal portions of the tether adjacent to and on opposite sides of the pulley define an angle therebetween of at least 120 degrees.
  • the angle is at least 135 degrees.
  • implanting the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system includes positioning the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system such that two longitudinal portions of the tether adjacent to and on opposite sides of the pulley define an angle there between of less than 90 degrees.
  • the angle is less than 60 degrees.
  • the second atrial tissue anchor includes (a) a tissue- coupling element, and (b) a head, which includes the pulley, and implanting the second atrial tissue anchor includes implanting the head.
  • the head includes an interface, which (a) includes the pulley, and (b) is rotatable with respect to the tissue-coupling element.
  • the pulley includes an eyelet.
  • the pulley includes a roller.
  • the pulley includes a flexible longitudinal member that is connected to the head at two points along the flexible longitudinal member, so as to define a loop longitudinally between the two points.
  • the tissue-coupling element is helical.
  • the third atrial tissue anchor includes a helical tissue-coupling element.
  • a first venous tissue anchor in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus, exactly two atrial tissue anchors, which consist of second and third atrial tissue anchors, at respective different atrial sites, each of which sites is selected from the group of sites consisting of: an annulus of a tricuspid valve, and a wall of a right atrium of a heart above the annulus of the tricuspid valve, and
  • a pulley system which includes (a) a pulley, which is connected to the first venous tissue anchor, (b) a first tether, which (i) is connected to the second and the third atrial tissue anchors, (ii) is moveable through the pulley, and (iii) has a first length, measured between the second and the third atrial tissue anchors, of at least 10 mm, and (c) a second tether, which (i) is connected to the first venous tissue anchor and to the pulley, and (ii) has a second length, measured between the first venous tissue anchor and the pulley, of at least 30 mm; and
  • the pulley includes a loop, and tensioning the first tether includes sliding the first tether through the loop.
  • a coefficient of kinetic friction between the first tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop is a closed loop.
  • the pulley includes a ring, and tensioning the first tether includes sliding the first tether through the ring.
  • a coefficient of kinetic friction between the first tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • the first venous tissue anchor includes an intraluminal stent, and implanting the first venous tissue anchor includes expanding the stent in the selected vein.
  • the second and the third atrial tissue anchors include respective helical tissue-coupling elements, and implanting the second and the third atrial tissue anchors includes rotating the helical tissue-coupling elements into tissue at the sites, respectively.
  • implanting the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system includes positioning the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system such that two longitudinal portions of the first tether adjacent to and on opposite sides of the pulley define an angle therebetween of at least 120 degrees.
  • positioning the first venous tissue anchor, the second atrial tissue anchor, the third atrial tissue anchor, and the pulley system such that the two longitudinal portions of the first tether adjacent to and on the opposite sides of the pulley define an angle therebetween of at least 135 degrees.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the inferior vena cava.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the superior vena cava.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal- leaflet of the tricuspid valve.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the coronary sinus.
  • implanting the third atrial tissue anchor includes implanting the third atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a septoanterior commissure of the tricuspid valve.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to a circumferential middle of a septal leaflet of the tricuspid valve.
  • a pulley system which includes (a) a pulley, (b) a first tether, which (i) is connected to the second and the third tissue anchors, (ii) is moveable through the pulley, and (iii) has a first length, measured between the second and the third tissue anchors, of at least 15 mm, and (c) a second tether, which (i) is connected to the first tissue anchor and to the pulley, and (ii) has a second length, measured between the first tissue anchor and the pulley, of at least 15 mm; and
  • implanting the first, the second, and the third tissue anchors includes implanting exactly three tissue anchors, which consist of the first, the second, and the third tissue anchors, and no other tissue anchors.
  • the pulley includes a loop, and tensioning the second tether includes sliding the first tether through the loop.
  • a coefficient of kinetic friction between the first tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop is a closed loop.
  • the pulley includes a ring, and tensioning the second tether includes sliding the first tether through the ring.
  • a coefficient of kinetic friction between the first tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • implanting the first anchor includes implanting the first anchor in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the first tissue anchor includes an intraluminal stent, and implanting the first tissue anchor includes implanting the stent in the selected vein.
  • the second and third tissue anchors include respective helical tissue-coupling elements, and implanting the second and the third tissue anchors includes rotating the helical tissue-coupling elements into tissue at the sites, respectively.
  • implanting the third tissue anchor includes implanting the third tissue anchor in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the third tissue anchor includes an intraluminal stent, and implanting the third tissue anchor includes implanting the stent in the selected vein.
  • the first and the second tissue anchors include respective helical tissue-coupling elements, and implanting the first and the second tissue anchors includes rotating the helical tissue-coupling elements into tissue at the sites, respectively.
  • a first tissue anchor which includes (a) a tissue-coupling element and (b) a head,
  • a pulley system which includes (a) a pulley, which is connected to the head of the first tissue anchor, and (b) a tether, which (i) is connected to the second and the third tissue anchors, (ii) is moveable through the pulley, and (iii) has a length, measured between the second and the third tissue anchors, of at least
  • the head is rigid.
  • the head includes an interface that is rotatable with respect to the tissue-coupling element.
  • the pulley includes a loop, and tensioning the tether includes sliding the tether through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop is a closed loop.
  • the pulley includes a ring, and tensioning the tether includes sliding the tether through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel.
  • implanting the third tissue anchor includes implanting the third tissue anchor in a vein selected from the group of veins consisting of: a superior vena cava, an inferior vena cava, and a coronary sinus.
  • the third tissue anchor includes an intraluminal stent, and implanting the third tissue anchor includes implanting the stent in the selected vein.
  • the tissue-coupling element of the first tissue anchor includes a first helical tissue-coupling element
  • the second tissue anchor includes a second helical tissue- coupling element
  • implanting the first and the second tissue anchors includes rotating the first and the second helical tissue-coupling elements into tissue, respectively.
  • a first venous tissue anchor in a vein selected from the group of veins consisting of: a superior vena cava and an inferior vena cava,
  • a second atrial tissue anchor at an atrial site selected from the group of sites consisting of: an annulus of a tricuspid valve, and a wall of a right atrium of a heart above the annulus of the tricuspid valve,
  • a pulley system which includes (a) a pulley, which is connected to the second atrial tissue anchor, and (b) a tether, which (i) is connected to the first and the third venous tissue anchors, (ii) is moveable through the pulley, and (iii) has a length, measured between the first venous and the third atrial tissue anchors, of at least 15 mm; and
  • the pulley includes a loop, and tensioning the tether includes sliding the tether through the loop.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the loop is a closed loop.
  • the pulley includes a ring, and tensioning the tether includes sliding the tether through the ring.
  • a coefficient of kinetic friction between the tether and the ring is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • the pulley includes a wheel, and tensioning the tether includes rotating the wheel by moving the tether through the pulley. For some applications:
  • first and the third venous tissue anchor include first and second intraluminal stents, respectively,
  • implanting the first venous tissue anchor includes expanding the first stent in the selected vein
  • implanting the third venous tissue anchor includes expanding the second stent in the coronary sinus.
  • a greatest outer diameter of the second intraluminal stent is no more than 80% of a greatest outer diameter of the first intraluminal stent, when the first and the second stents are unconstrained and fully radially expanded.
  • the second atrial tissue anchor includes a helical tissue-coupling element, and implanting the second atrial tissue anchor includes rotating the helical tissue-coupling element into tissue at the site.
  • implanting the first venous tissue anchor, the second atrial tissue anchor, the third venous tissue anchor, and the pulley system includes positioning the first venous tissue anchor, the second atrial tissue anchor, the third venous tissue anchor, and the pulley system such that two longitudinal portions of the tether adjacent to and on opposite sides of the pulley define an angle therebetween of between 120 and 180 degrees.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the inferior vena cava.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • implanting the first venous tissue anchor includes implanting the first venous tissue anchor in the superior vena cava.
  • implanting the second atrial tissue anchor includes implanting the second atrial tissue anchor within 1 cm of a site on the annulus that circumferentially corresponds to an anteroposterior commissure of the tricuspid valve.
  • the tether is a first tether; the length is a first length; the pulley system further includes a second tether, which (a) is connected to the pulley and the second atrial tissue anchor, so as to connect the pulley to the second atrial tissue anchor, and (b) has a second length, measured between the second atrial tissue anchor and the pulley, of at least 3 mm; and implanting the pulley system further includes implanting the second tether.
  • the second atrial tissue anchor includes (a) a tissue- coupling element, and (b) a head; the pulley is connected to the head; and tensioning the tether includes fully extending the pulley away from the head, such that a distance between (a) a site on the pulley farthest from the head and (b) a site on the head closest to the pulley, is at least 3 mm.
  • the head is rigid.
  • the head includes an interface that is rotatable with respect to the tissue- coupling element.
  • the second atrial tissue anchor includes (a) a tissue-coupling element, and (b) a head, which includes the pulley, and implanting the second atrial tissue anchor includes implanting the head.
  • the head includes an interface, which (a) includes the pulley, and (b) is rotatable with respect to the tissue- coupling element.
  • the pulley includes an eyelet.
  • the pulley includes a roller.
  • the pulley includes a flexible longitudinal member that is connected to the head at two points along the flexible longitudinal member, so as to define a loop longitudinally between the two points.
  • the tissue-coupling element is helical.
  • first and second tissue anchors are removably positioned in the catheter shaft at first and second longitudinal locations, respectively, the first longitudinal location more distal than the second longitudinal location
  • first and the second tissue anchors include (i) first and second helical tissue-coupling elements, respectively, and (ii) first and second heads, respectively, which include first and second tether interfaces, and (b) a tether, which is connected to the first tether interface, and is coupled to the second tether interface, is removably positioned in the catheter shaft
  • the multiple-anchor delivery tool includes first and second torque cables, which (a) are removably coupled to the first and the second heads, respectively, (b) extend within the catheter shaft proximally from the first and the second heads, respectively, and (c) transmit torque when rotated, wherein a portion of the first torque cable is removably positioned alongside the
  • the first torque cable is shaped so as to define a lumen therethrough;
  • the multiple-anchor delivery tool further includes a sharpened wire, which removably passes through the lumen, and which is initially positioned such that a distal end of the sharpened wire extends distally out of a distal end of the lumen; and the method further includes withdrawing the sharpened wire proximally.
  • the head is shaped so as to define a proximal coupling element
  • the head including the proximal coupling element, is shaped so as to define a first longitudinal channel at least partially therethrough, which channel is coaxial with the head,
  • a distal end of the first torque cable includes a distal coupling element, which is shaped so as to define a second longitudinal channel therethrough, which channel is coaxial with the lumen of the first torque cable,
  • the proximal and the distal coupling elements are shaped so as to define corresponding interlocking surfaces, the sharpened wire, when disposed through the first and the second channels, prevents decoupling of the distal coupling element from the proximal coupling element, and
  • withdrawing the sharpened wire proximally includes decoupling the distal coupling element from the proximal coupling element by withdrawing the sharpened wire proximally.
  • the sharpened wire is shaped so as to define a sharp distal tip.
  • implanting the first tissue anchor includes inserting the sharp distal tip of the sharpened wire into the tissue.
  • advancing includes advancing the distal end of the catheter shaft into the body while (a) a third tissue anchor is removably positioned in the catheter shaft at a third longitudinal location that is more proximal than the second longitudinal location, the third tissue anchor includes (i) a third helical tissue-coupling elements and (ii) a third head, which includes a third tether interface, (b) the tether is coupled to the third tether interface,
  • the multiple-anchor delivery tool further includes a third torque cable, which (a) is removably coupled to the third head, (b) extends within the catheter shaft proximally from the third head, and (c) transmits torque when rotated, a portion of the second torque cable is removably positioned alongside the third tissue anchor in the catheter shaft, and
  • the method further includes:
  • the first tether interface is rotatable with respect to the first tissue-coupling element.
  • Fig. 1 is a schematic illustration of a valve-tensioning implant, in accordance with an application of the present invention
  • Figs. 2A-D are schematic illustrations of several configurations of a pulley of the valve-tensioning implant of Fig. 1, in accordance with respective applications of the present invention
  • Figs. 3A-0 are schematic illustrations of implantations of the valve-tensioning implant of Fig. 1, in accordance with respective applications of the present invention
  • Fig. 4 is a schematic illustration of another valve-tensioning implant, in accordance with an application of the present invention.
  • Figs. 5A-B are schematic illustrations of two configurations of a pulley of the valve-tensioning implant of Fig. 4, in accordance with respective applications of the present invention
  • Figs. 6A-I are schematic illustrations of implantations of the valve-tensioning implant of Fig. 4, in accordance with respective applications of the present invention.
  • Fig. 7 is a schematic illustration of yet another valve-tensioning implant, in accordance with an application of the present invention.
  • FIGS. 8A-H are schematic illustrations of implantations of the valve-tensioning implant of Fig. 7, in accordance with respective applications of the present invention
  • Figs. 9A and 9B are schematic illustrations of a delivery system comprising a multiple-anchor delivery tool, in accordance with respective applications of the present invention.
  • Figs. lOA-C are schematic illustrations of a deployment method using the multiple-anchor delivery tool and implant shown in Fig. 9B, in accordance with an application of the present invention
  • Figs. 1 1 A-D are schematic illustrations of a delivery system comprising respective multiple-anchor delivery tools, in accordance with respective applications of the present invention.
  • Figs. 12A-C are schematic illustrations of the deployment of a valve-tensioning implant system using the multiple-anchor delivery tool of Fig. 11 A, in accordance with an application of the present invention.
  • Fig. 1 is a schematic illustration of a valve-tensioning implant system 20, in accordance with an application of the present invention.
  • Valve-tensioning implant system 20 is configured to repair an atrioventricular valve of a subject (e.g., a tricuspid valve), using tension applied between multiple anchors of the implant.
  • atrioventricular valve facilitates a reduction in atrioventricular valve regurgitation by altering the geometry of the atrioventricular valve and/or by altering the geometry of the wall of the right or left atrium of a heart of the subject.
  • valve-tensioning implant system 20 comprises a first venous tissue anchor 30, such as exactly one first venous tissue anchor 30.
  • First venous tissue anchor 30 is configured to be implanted at an implantation site upstream of the atrioventricular valve.
  • first venous tissue anchor 30 is typically configured to be implanted in a vein selected from the group of veins consisting of: a superior vena cava (SVC) 110 (such as described hereinbelow with reference to Figs. 3E-H, 3M, and 30), an inferior vena cava (IVC) 80 (such as described hereinbelow with reference to Figs. 3A-D, 31, and 3L), and a coronary sinus 115 (such as described hereinbelow with reference to Figs. 3J- M).
  • Valve-tensioning implant system 20 further comprises second and third atrial tissue anchors 40 and 42.
  • valve-tensioning implant system 20 comprises exactly two atrial tissue anchors, which consist of second and third atrial tissue anchors 40 and 42.
  • Valve-tensioning implant system 20 further comprises a pulley system 44, which comprises: ⁇ a pulley 50, which is connected (e.g., permanently fixed) to second atrial tissue anchor 40; and
  • a tether 54 which is connected (e.g., permanently fixed) to first venous anchor 30 and third atrial tissue anchor 42, and is moveable through pulley 50.
  • Tether 54 comprises an elongate flexible element, such as a cord, suture, or band.
  • tether 54 has a high tensile strength and low friction, in order to enable the tether to apply tension, as described hereinbelow.
  • tether 54 has a length, measured between first venous tissue anchor 30 and third atrial tissue anchor 42, of at least 15 mm, no more than 200 mm, and/or between 15 and 200 mm, such at least 30 mm, no more than 120 mm, and/or between 30 and 120 mm.
  • the length equals the sum of (a) a first sub-length LI of a first portion of the tether between first venous tissue anchor 30 and pulley 50 and (b) a second sub-length L2 of a second portion of the tether between pulley 50 and third atrial tissue anchor 42.
  • First and second sub-lengths LI and L2 are not fixed, because tether 54 is both moveable through pulley 50 as well as rotatable around the pivot point; however, the sum of the two sub-lengths is fixed.
  • tether 54 typically has a high tensile strength, the length thereof does not vary based on the particular disposition of the tether at any given point in time.
  • tether 54 is configured so as to define an anchor-fixing loop 66, which passes through a corresponding interface (e.g., defined by struts of the stent) on first venous tissue anchor 30, so as to connect (e.g., permanently fix) the tether to the first venous tissue anchor.
  • an anchor-fixing loop 66 which passes through a corresponding interface (e.g., defined by struts of the stent) on first venous tissue anchor 30, so as to connect (e.g., permanently fix) the tether to the first venous tissue anchor.
  • tether 54 comprises two separate sections 54A and 54B, which may be connected by an intraluminal locking mechanism 55 that comprises coupling elements (e.g., male and female coupling elements), which are connected during the implantation procedure, such as in order to allow implantation of first venous tissue anchor 30 with a separate catheter delivery system, such as described in US Patent Application Publication 2013/0018459, which is assigned to the assignee of the present application, and is incorporated herein by reference, such as with reference to Figs. 20-32 thereof.
  • coupling elements e.g., male and female coupling elements
  • Figs. 2A-D are schematic illustrations of several configurations of pulley 50, in accordance with respective applications of the present invention.
  • a pulley is an element that transfers force along a tether, changing a direction of the force without substantially changing a magnitude of the force, while the tether moves through the pulley.
  • a pulley need not comprise a wheel, as is common in conventional pulleys. For some applications, a wheel is not necessary because the movement required during the cardiac cycle is reciprocal (back-and-forth) in nature, and limited in magnitude, about a few millimeters in each direction.
  • tissue growth may inhibit or entirely obstruct the tether's movement through the pulley, thereby disabling the pulley's "pulley” functionality.
  • the feature that the tether is moveable through the pulley characterizes the pulley system at least at the time of implantation, but not necessarily after implantation.
  • pulley 50 comprises a loop 52, through which tether 54 is slidably moveable.
  • a coefficient of kinetic friction between the tether and the loop is less than 0.5, such as less than 0.2, e.g., less than 0.1.
  • loop 52 comprises a closed loop; in other words, the ends of the loop are joined together.
  • loop 52 comprises an open loop; both ends of the cord that defines the loop are connected (e.g., permanently fixed) to second atrial tissue anchor 40, but not to one another.
  • pulley 50 comprises a flexible longitudinal member that is connected (e.g., permanently fixed) to the head of anchor 40 at two points along the flexible longitudinal member, so as to define loop 52 longitudinally between the two points.
  • pulley 50 comprises a ring 60, through which tether 54 is slidably moveable.
  • a coefficient of kinetic friction between tether 54 and ring 60 is less than 0.5, such as less 0.2, e.g., less than 0.1.
  • pulley 50 comprises a wheel 62 on an axle that supports movement of tether 54 along the wheel's circumference.
  • Wheel 62 typically is shaped so as to define a groove between two flanges around its circumference, as is well-known in the pulley art.
  • Pulley 50 may alternatively comprise an eyelet or a roller, such as described hereinbelow with reference to Figs. 4 and 5A-B.
  • first venous tissue anchor 30 comprises an intraluminal stent 46.
  • the stent is configured to be implanted in the vein by applying an outward radial force to the wall of the vein.
  • the stent is configured to self-expand.
  • the stent may comprise a shape-memory alloy, such as Nitinol.
  • the stent comprises a deformable metal, and is expanded by a tool, such as a balloon.
  • stent 46 comprises a plurality of interconnected superelastic metallic struts, arranged so as to allow crimping the stent into a relatively small diameter (typically less than 8 mm) catheter, while allowing deployment to a much larger diameter (typically more than 20 mm) in the vein, while still maintaining radial force against the tissue of the wall of the vein, in order to anchor stent 46 to the wall of the vein by friction.
  • the stent is configured to not penetrate tissue of the wall of the vein.
  • stent 46 implements techniques described in US Provisional Application 61/783,224, filed March 14, 2013, which is assigned to the assignee of the present application and is incorporated herein by reference.
  • second and third atrial tissue anchors 40 and 42 comprise respective helical tissue-coupling elements 48A and 48B, which puncture and screw into the cardiac muscle tissue.
  • second and third atrial tissue anchors 40 and 42 implement techniques described in US Provisional Application 61/750,427, filed January 9, 2013.
  • each of second and third atrial tissue anchors 40 and 42 comprises a clip, jaws, or a clamp which grips and squeezes a portion of cardiac muscle tissue and does not puncture the cardiac muscle tissue.
  • tether 54 is a first tether 54, and the length of first tether 54 is a first length.
  • Pulley system 44 further comprises a second tether 56, which is connected (e.g., permanently fixed) to pulley 50 and second atrial tissue anchor 40, so as to fix pulley 50 to second atrial tissue anchor 40.
  • Second tether 56 comprises an elongate flexible element, such as a cord, a suture, or a band (e.g., a textile band).
  • second tether 56 has a high tensile strength.
  • second tether 56 has a second length L3, measured between second atrial tissue anchor 40 and pulley 50, of at least 3 mm, no more than 20 mm, and/or between 3 and 20 mm, such as at least 5 mm, no more than 8 mm, and/or between 5 and 8 mm. Because second tether 56 typically has a high tensile strength, the length thereof does not vary based on the particular disposition of the second tether at any given point in time. In other words, the length of the second tether does not depend on the tensile forces applied to it.
  • the second length equals at least 10% of the first length, no more than 50% of the first length, and/or between 10% and 50% of the second length, such as at least 20% of the first length, no more than 40% of the second length, and/or between 20% and 40% of the second length.
  • second tether 56 is configured so as to define an anchor-fixing loop 68, which passes through a corresponding interface on second atrial tissue anchor 40, so as to connect (e.g., permanently fix) the second tether to the second atrial tissue anchor.
  • second atrial tissue anchor 40 comprises (a) tissue-coupling element 48A (which is optionally helical) and (b) a head 70.
  • Pulley 50 is connected (e.g., permanently fixed) to head 70 such that, when pulley 70 is fully extended away from the head, a distance Dl between (a) a site 72 on pulley 50 farthest from head 70 and (b) a site 74 on head 70 closest to pulley 50, is at least 3 mm (e.g., at least 5 mm), no more than 40 mm, and/or between 3 and 40 mm or between 5 and 40 mm.
  • distance Dl equals at least 10% of the length of tether 54, no more than 50% of the length of tether 54, and/or between 10% and 50% of the length of tether 54.
  • head 70 comprises a tether interface 71, to which second tether 56 is connected (such as by anchor-fixing loop 68).
  • tether interface 71 is rotatable with respect to tissue- coupling element 48A.
  • head 70 is rotatable with respect to tissue- coupling element 48A, so that tether interface 71 is rotatable with respect to tissue- coupling element 48A.
  • tether interface 71 is rotatable with respect to head 70 (which may be rotationally fixed with respect to tissue-coupling element 48A), such that tether interface 71 is rotatable with respect to tissue-coupling element 48A.
  • Figs. 3A-0 are schematic illustrations of implantations of valve-tensioning implant system 20, in accordance with respective applications of the present invention.
  • the implantations are typically performed transvascularly, using a delivery system comprising one or more catheters introduced with the aid of a guidewire, through vasculature of the subject, such as (a) via the femoral vein, through inferior vena cava 80, and into a right atrium 81 , (b) via the basilic vein, through the subclavian vein through superior vena cava 110, and into right atrium 81, or (c) via the external jugular vein, through the subclavian vein through superior vena cava 110, and into right atrium 81.
  • a delivery system comprising one or more catheters introduced with the aid of a guidewire, through vasculature of the subject, such as (a) via the femoral vein, through inferior vena cava 80, and into a right atrium 81 , (b) via the basil
  • the procedure is typically performed with the aid of imaging, such as fluoroscopy, transesophageal echo, and/or echocardiography.
  • the procedure may be performed using techniques described in US Patent Application Publication 2012/0035712, which is assigned to the assignee of the present application and is incorporated herein by reference, with reference to Figs. 1A-D thereof, mutatis mutandis, and/or using techniques described hereinbelow with reference to Figs. 9A-B, l A-C, 11A-D, and/or 12A-C, mutatis mutandis.
  • Second and third atrial tissue anchors 40 and 42 are implanted at respective different second atrial sites 90 and 92, each of which sites is selected from the group of sites consisting of: an annulus 83 of a tricuspid valve 78, and a wall of right atrium 81 of the heart above annulus 83.
  • second and third atrial tissue anchors 40 and 42 comprise respective helical tissue-coupling elements 48 A and 48B, the helical tissue-coupling elements are rotated into tissue at the sites, respectively.
  • First venous tissue anchor 30 is implanted at a first site 89 in a vein selected from the group of veins consisting of: superior vena cava 1 10 (as shown, for example, in Figs. 3E-H, 3M, and 30), inferior vena cava 80 (as shown, for example, in Figs. 3A-D, 31, and 3L), and coronary sinus 1 15 (as shown, for example, in Figs. 3J-K).
  • first venous tissue anchor 30 comprises intraluminal stent 46
  • the stent is expanded in the selected vein in order to anchor the stent to the wall of the vein by the outward radial force applied by the stent.
  • first, second, and third sites 89, 90, and 92, and of first, second, and third tissue anchors 30, 40, and 42 are to be understood only as convenient references to distinguish the sites and anchors from one another, and are not to be understood as implying or requiring any order of implantation or of other properties of the sites or anchors.
  • intraluminal stent 46 typically has a greatest outer diameter of between 25 and 55 mm, when unconstrained and fully radially expanded, i.e., no forces are applied to the stent by a delivery tool, walls of a blood vessel, or otherwise.
  • intraluminal stent 46 typically has a greatest outer diameter of between 5 and 20 mm, when unconstrained and fully radially expanded (the stent may somewhat enlarge the coronary sinus).
  • tensioning tether 54 comprise fully extending pulley 50 away from head 70, such that distance Dl, described hereinabove, between (a) site 72 on pulley 50 farthest from head 70 and (b) site 74 on head 70 closest to pulley 50, is at least 3 mm (e.g., at least 5 mm), no more than 40 mm, and/or between 3 and 40 mm or between 5 and 30 mm.
  • Pulley system 44 enables the controlled, uneven distribution of forces on tissue at first, second, and third implantation sites 89, 90, and 92.
  • a force vector VI on the tissue at second implantation site 90 which is connected (e.g., permanently fixed) to pulley 50 by second anchor 40, equals the vector sum of force vectors V2 and V3 acting on tissue at first and third implantation sites 89 and 92, respectively, which are connected (e.g., permanently fixed) to tether 54 by first venous tissue anchor 30 and third atrial tissue anchor 42, respectively.
  • the forces acting on first and third implantation sites 89 and 92 are less than the force acting on second implantation site 90 (to which the pulley is fixed).
  • This controlled distribution of forces may be particularly beneficial if, for example:
  • second implantation site 90 (to which the pulley is fixed) is located in a region of tissue which is thicker or stronger than first and third implantation sites 89 and 92.
  • tissue of the septum between the ventricles is thicker and stronger than the atrium wall and the vena cava wall;
  • the anchoring mechanism of the anchor to which the pulley is connected anchors using mechanical purchase, e.g., using a helical anchor, while the anchoring mechanism of at least one of the other anchoring points (e.g., first implantation site 89) is friction based, e.g., using an intraluminal stent; and/or
  • the force vectors acting on first implantation site 89 and second implantation site 90 are aligned along a preferable direction which causes constriction of the tricuspid valve in a more favorable manner than tensioning towards third implantation site 92 alone.
  • the sites may be selected apply the maximum force on the implantation site that is desired to be moved.
  • the tissue anchors and pulley system 44 are arranged such that the vector sum of the forces on all of the implantation sites is zero, and the force vector on second implantation site 90 (to which the pulley is fixed) is the vector sum of the forces acting on first and third implantation sites 89 and 92.
  • Equation 1 The scalar force acting on first and third implantation sites 89 and 92 depends on an angle a (alpha) (labeled in Fig. 1) formed by tether 54 at pulley 50, and may be expressed by the following equation: (Equation 1)
  • F s is the force acting on each of the first and third implantation sites 89 and 92;
  • Fp is the force acting on second implantation site 90 (to which the pulley is fixed).
  • a (alpha) is the angle formed by tether 54 at pulley 50 (sometimes referred to in the pulley art as the "included angle").
  • the force acting on each of first and third implantation sites 89 and 92 is less than the force acting on second implantation site 90 (to which the pulley is fixed).
  • the force acting on each of first and third implantation sites 89 and 92 is approximately 50% of the force acting on second implantation site 90 when angle a (alpha) is 45 degrees or less.
  • angle a (alpha) is defined by two longitudinal portions 58A and 58B (labeled in Fig.
  • angle a is acute (less than 90- degree), typically between 40 and 85 degrees, typically as close as possible to 45 degrees or lower.
  • a kit for some applications in which pulley system 44 further comprises second tether 56, a kit is provided that comprises a plurality of pulleys 50 connected (e.g., permanently fixed) to a respective plurality of second tissue anchors 40 by respective second tethers 56 having different respective lengths.
  • the surgeon selects an appropriate pulley/second tether/second anchor assembly based on the particular anatomy of the subject, in order to achieve a desired angle a (alpha).
  • the length of the second tether affects the location of the pulley.
  • valve-tensioning implant system 20 comprises a single pulley, a single second tether, and a single second anchor, and the second tether has an adjustable length, which the surgeon can set before and/or during the implantation procedure as appropriate for the particular anatomy of the subject. Either option provides for an adjustable distance Dl, as described hereinabove with reference to Fig. 1.
  • the following table sets forth exemplary combinations of first implantation site 89 and anatomical markers for second and third implantation sites 90 and 92, and figures that show exemplary deployments at these sites. These sites are listed by way of example and not limitation; the surgeon typically selects the exact sites based on the subject's individual needs and anatomy.
  • Each of second and third implantation sites 90 and 92 is located within 1 cm of the site on the annulus that circumferentially corresponds to the respective anatomical marker (i.e., is at the same angular location or "o'clock" as the respective anatomical marker).
  • the direction of the 1 cm from the site on the annulus may be either circumferentially (i.e., clockwise or counterclockwise) around the annulus, up the wall of right atrium 81 above annulus 83, or a combination of circumferentially around the annulus and up the wall of the atrium. For example, as shown in Fig.
  • anteroposterior commissure 112 is near, but not on, the annulus, and second tissue anchor 40 is shown implanted at second implantation site 90, which is at the site on the annulus that circumferentially corresponds to this commissure.
  • Second implantation site 90 could also be up to 1 cm clockwise or counterclockwise around the annulus from this site on the annulus, up to 1 cm up the wall of the atrium, or a combination of these two directions.
  • the surgeon uses the anatomical markers to find the exact locations of second and third implantation sites 90 and 92, which are within 1 cm of the anatomical markers, as described above.
  • the commissures are easily detectable using imaging, and thus represent good anatomical markers.
  • the commissures are not appropriate for implantation (because they are too delicate), so, in this example, the anchors are implanted on the annulus or up the wall of the atrium, within 1 cm from the commissure.
  • Inferior vena cava 80 Anteroposterior Septoanterior Fig. 3B commissure 112 commissure 114
  • Inferior vena cava 80 A circumferential Anteroposterior Fig. 3C middle 93 of septal commissure 112
  • Superior vena cava 110 Anteroposterior Circumferential middle Fig. 3G commissure 112 93 of septal leaflet 82
  • Inferior vena cava 80 A circumferential A circumferential middle Fig. 31 middle 121 of anterior 119 of posterior leaflet
  • Coronary sinus 115 Anteroposterior Septoanterior Fig. 3J commissure 1 12 commissure 114
  • an implantation method comprises implanting first venous tissue anchor 30 at first implantation site 89 in inferior vena cava 80.
  • second atrial tissue anchor 40 is implanted at second implantation site 90 which is located within 1 cm of a site on the annulus that circumferentially corresponds to circumferential middle 93 of septal leaflet 82 of tricuspid valve 78
  • third atrial tissue anchor 42 is implanted at third implantation site 92 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 112 of tricuspid valve 78.
  • second atrial tissue anchor 40 is implanted at second implantation site 90 which is located within 1 cm of a site on the annulus that circumferentially corresponds to septoanterior commissure 114 of tricuspid valve 78
  • third atrial tissue anchor 42 is implanted at third implantation site 92 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 112 of tricuspid valve 78.
  • third tissue anchor 42 comprises a third venous tissue anchor, rather than an atrial tissue anchor.
  • third tissue anchor 42 typically comprises an intraluminal stent 146 that is configured to be implanted in coronary sinus 115.
  • Intraluminal stent 146 typically has a greatest outer diameter of at least 10 mm, no more than 20 mm, and/or between 10 to 20 mm, when unconstrained and fully radially expanded.
  • the greatest outer diameter of intraluminal stent 146 is less than the greatest outer diameter of intraluminal stent 46, when both stents are unconstrained and fully radially expanded.
  • valve-tensioning implant system 120 is similar to, and may implement any of the features of, valve-tensioning implant system 20, described hereinabove with reference to Figs. 1-30.
  • Valve-tensioning implant 120 is configured to repair an atrioventricular valve of a subject (e.g., a tricuspid valve), using tension applied between multiple anchors of the implant.
  • repair of the atrioventricular valve facilitates a reduction in atrioventricular valve regurgitation by altering the geometry of the atrioventricular valve and/or by altering the geometry of the wall of the right or left atrium of a heart of the subject.
  • valve-tensioning implant system 120 comprises first venous tissue anchor 30, which is configured to be implanted in a vein selected from the group of veins consisting of: superior vena cava 1 10, inferior vena cava 80, and coronary sinus 115, such as described hereinbelow with reference to Figs. 6A-I.
  • First venous tissue anchor 30 may have any of the features described hereinabove with reference to Fig. 1.
  • Valve-tensioning implant system 120 further comprises a second atrial tissue anchor 140 and third atrial tissue anchor 42.
  • valve-tensioning implant system 120 comprises exactly two atrial tissue anchors, which consist of second and third atrial tissue anchors 140 and 42.
  • Second atrial tissue anchor 140 comprises a head 170 and a tissue-coupling element 174.
  • head 170 is rotatable with respect to tissue-coupling element 174.
  • Second and third atrial tissue anchors 140 and 42 may have any of the features of second and third atrial tissue anchors 40 and 42, described hereinabove with reference to Fig. 1.
  • Valve-tensioning implant system 120 further comprises a pulley system 144, which comprises (a) a pulley 150, which is connected (e.g., permanently fixed) to second atrial tissue anchor 140, and (b) tether 54 (described hereinabove with reference to Fig. 1), which is connected (e.g., permanently fixed) to first venous anchor 30 and third atrial tissue anchor 42, and is moveable through pulley 150.
  • Head 170 comprises pulley 150.
  • head 170 comprises a tether interface 171, which comprises pulley 150.
  • tether interface 171 and/or pulley 150 are rotatable with respect to tissue-coupling element 174.
  • tether 54 typically has a length, measured between first venous tissue anchor 30 and third atrial tissue anchor 42, of at least 20 mm, no more than 200 mm, and/or between 20 and 200 mm, such at least 30 mm, no more than 120 mm, and/or between 30 and 120 mm.
  • the length equals the sum of (a) a first sub-length L4 of a first portion of the tether between first venous tissue anchor 30 and pulley 150 and (b) a second sub-length L5 of a second portion of the tether between pulley 150 and third atrial tissue anchor 42.
  • First and second sub-lengths L4 and L5 are not fixed, because tether 54 is both moveable through pulley 50 as well as rotatable around the pivot point; however, the sum of the two sub-lengths is fixed.
  • tether 54 typically has a high tensile strength, the length thereof does not vary based on the particular disposition of the tether at any given point in time.
  • tether 54 is configured so as to define anchor-fixing loop 66, which passes through a corresponding interface (e.g., defined by struts of a stent) on first venous tissue anchor 30, so as to connect (e.g., permanently fix) the tether to the first venous tissue anchor.
  • anchor-fixing loop 66 passes through a corresponding interface (e.g., defined by struts of a stent) on first venous tissue anchor 30, so as to connect (e.g., permanently fix) the tether to the first venous tissue anchor.
  • pulley 150 comprises an eyelet 172, through which tether 54 is slidably moveable.
  • a coefficient of kinetic friction between the tether and the eyelet is less than 0.5, such as less than 0.2, e.g., less than 0.1.
  • Figs. 5A-B are schematic illustrations of two configurations of pulley 150, in accordance with respective applications of the present invention.
  • pulley 150 comprises a roller 176, which is rotatable with respect to head 170, and around which tether 54 passes.
  • the roller axis is oriented parallel with a longitudinal axis of head 170, while for other applications, such as shown in Fig. 5B, the roller axis is oriented perpendicular to the longitudinal axis of head 170.
  • Figs. 6A-I are schematic illustrations of implantations of valve-tensioning implant system 120, in accordance with respective applications of the present invention.
  • the implantations are typically performed transvascularly, such as described hereinabove with reference to Figs. 3A-0.
  • First venous tissue anchor 30 is implanted at first site 89 in a vein selected from the group of veins consisting of: inferior vena cava 80 (as shown, for example, in Figs. 6A-D), superior vena cava 110 (as shown, for example, in Figs. 6E-G), and coronary sinus 115 (as shown, for example, in Figs. 6H-I).
  • first venous tissue anchor 30 comprises intraluminal stent 46
  • the stent is expanded in the selected vein in order to anchor the stent to the wall of the vein by the outward radial force applied by the stent.
  • Second and third atrial tissue anchors 140 and 42 are implanted at respective different second atrial sites 190 and 192, each of which sites is selected from the group of sites consisting of: annulus 83 of tricuspid valve 78, and a wall of right atrium 81 above annulus 83.
  • second and third atrial tissue anchors 140 and 42 comprise respective helical tissue-coupling elements 174 and 48B, the helical tissue-coupling elements are rotated into tissue at the sites, respectively.
  • Pulley system 144 is implanted (including by implanting second atrial tissue anchor 140). For applications in which intraluminal locking mechanism 55 is used, the male and female coupling elements thereof are locked together. A size of a tricuspid orifice is reduced by tensioning tether 54, so as to reduce regurgitation.
  • first, second, and third sites 89, 190, and 192, and of first, second, and third tissue anchors 30, 40, and 42 are to be understood only as convenient references to distinguish the sites and anchors from one another, and are not to be understood as implying or requiring any order of implantation or of other properties of the sites or anchors.
  • Pulley system 144 enables the controlled, uneven distribution of forces on tissue at first, second, and third implantation sites 89, 190, and 192.
  • a force vector V4 on the tissue at second implantation site 190 which is connected (e.g., permanently fixed) to pulley 150 by second anchor 140, equals the vector sum of force vectors V5 and V6 acting on tissue at first and third implantation sites 189 and 192, respectively, which are connected (e.g., permanently fixed) to tether 54 by first venous tissue anchor 30 and third atrial tissue anchor 42, respectively.
  • Force vectors V4, V5, and V6 are not drawn to scale in Fig. 4.
  • the forces acting on first and third implantation sites 89 and 192 are less than the force acting on second implantation site 190 (to which the pulley is fixed).
  • ⁇ second implantation site 190 (to which the pulley is fixed) is located in a region of tissue which is thicker or stronger than first and/or third implantation sites 89 and 192.
  • tissue of the septum between the ventricles is thicker and stronger than the atrium wall and the vena cava wall;
  • the anchoring mechanism of the anchor to which the pulley is not fixed performs anchoring using mechanical purchase, e.g., using a helical anchor, while the anchoring mechanism of another of the anchors the (e.g., at first implantation site 89) is friction based, e.g., using an intraluminal stent;
  • the forces vectors acting on first implantation site 89 and second implantation site 190 are aligned along a preferable direction which causes constriction of the tricuspid valve in a more favorable manner than tensioning towards third implantation site 192 alone.
  • the sites may be selected apply the maximum force on the implantation site that is desired to be moved.
  • the tissue anchors and pulley system 144 are arranged such that the vector sum of the forces on all of the implantation sites is zero, and the force vector on second implantation site 190 (to which the pulley is fixed) is the vector sum of the forces acting on first and third implantation sites 89 and 192.
  • the scalar force acting on first and third implantation sites 89 and 192 depends on an angle ⁇ (beta) (labeled in Fig. 4) formed by tether 54 at pulley 150, and may be expressed by Equation 1, described above with reference to Fig. 1, mutatis mutandis.
  • the force acting on each of first and third implantation sites 89 and 192 is equal to the force acting on second implantation site 190 when the angle is 120 degrees, and increases as the angle increases, to approximately 46% greater than the force acting on second implantation site 190 when the angle is 140 degrees.
  • Angle ⁇ (beta) is defined by two longitudinal portions 58A and 58B (labeled in Fig.
  • angle ⁇ (beta) is between 120 and 180 degrees, such as between 135 and 175 degrees, typically as close as possible to 180 degrees, which will result in zero force on the pulley point (although achieving 180 degrees is difficult, if not impossible, in practice).
  • second and third implantation sites 190 and 192 are located within 1 cm of the site on the annulus that circumferentially corresponds to the respective anatomical marker.
  • the direction of the 1 cm from the site may be either circumferentially around the annulus, up the wall of right atrium 81 above annulus 83, or a combination of circumferentially around the annulus and up the wall of the atrium.
  • an implantation method comprises implanting first venous tissue anchor 30 at first implantation site 89 in inferior vena cava 80.
  • second atrial tissue anchor 140 is implanted at second implantation site 190 which is located within 1 cm of a site on the annulus that circumferentially corresponds to circumferential middle 93 of septal leaflet 82 of tricuspid valve 78
  • third atrial tissue anchor 42 is implanted at third implantation site 192 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 112 of tricuspid valve 78.
  • valve-tensioning implant system 220 is similar to, and may implement any of the features of, valve-tensioning implant system 20, described hereinabove with reference to Figs. 1-30.
  • Valve-tensioning implant system 220 is configured to repair an atrioventricular valve of a subject (e.g., a tricuspid valve), using tension applied between multiple anchors of the implant.
  • repair of the atrioventricular valve facilitates a reduction in atrioventricular valve regurgitation by altering the geometry of the atrioventricular valve and/or by altering the geometry of the wall of the right or left atrium of a heart of the subject.
  • valve-tensioning implant system 220 comprises first venous tissue anchor 30, which is configured to be implanted in a vein selected from the group of veins consisting of: superior vena cava 1 10, inferior vena cava 80, and coronary sinus 115.
  • First venous tissue anchor 30 may have any of the features described hereinabove with reference to Fig. 1.
  • Valve-tensioning implant system 220 further comprises second and third atrial tissue anchors 40 and 42.
  • valve-tensioning implant system 220 comprises exactly two atrial tissue anchors, which consist of second and third atrial tissue anchors 40 and 42.
  • Second and third atrial tissue anchors 40 and 42 may have any of the features of second and third atrial tissue anchors 40 and 42, described hereinabove with reference to Fig. 1.
  • Valve-tensioning implant system 220 further comprises a pulley system 244, which comprises:
  • a pulley 250 which is connected (e.g., permanently fixed) to first venous tissue anchor 30; • a first tether 254, which (a) is connected (e.g., permanently fixed) to second and third atrial tissue anchors 40 and 42, (b) is moveable through pulley 250, and/or the pulley is rotatable around a pivot point, and (c) has a first length, measured between the second and the third atrial tissue anchors, of at least 10 mm, e.g., at least 15 mm, such as at least 20 mm, no more than 50 mm, and/or between 20 and
  • a second tether 256 which (a) is connected (e.g., permanently fixed) to first venous tissue anchor 30 and to pulley 250, and (b) has a second length L6, measured between first venous tissue anchor 30 and pulley 250, equal to at least 80% (e.g., at least 100%) of the first length, of at least 25 mm (e.g., at least 30 mm), no more than 180 mm, and/or between 25 mm (e.g., 30 mm) and 180 mm, e.g., no more than 120 mm and/or between 30 and 120 mm.
  • a second tether 256 which (a) is connected (e.g., permanently fixed) to first venous tissue anchor 30 and to pulley 250, and (b) has a second length L6, measured between first venous tissue anchor 30 and pulley 250, equal to at least 80% (e.g., at least 100%) of the first length, of at least 25 mm (e.g., at
  • First and second tethers 254 and 256 comprise respective elongate flexible elements, such as cords, sutures, or bands.
  • the tethers are typically sufficiently flexible for twisting or bending but are inelastic against tension.
  • first and second tethers 254 and 256 have a high tensile strength, in order to enable the tethers to apply tension, as described hereinbelow.
  • the first length equals the sum of (a) a first sub-length L7 of a first portion of first tether 254 between second atrial tissue anchor 40 and pulley 250 and (b) a second sub- length L8 of a second portion of first tether 254 between pulley 250 and third atrial tissue anchor 42.
  • First and second sub-lengths L7 and L8 are not fixed, because tether 54 is both moveable through pulley 50 as well as rotatable around the pivot point; however, the sum of the two sub-lengths is fixed.
  • the first and the second tethers typically have a high tensile strength, the lengths thereof do not vary based on the particular disposition of the first and the second tethers at any given point in time. In other words, the lengths of the tethers do not depend on the amount of force applied to them.
  • the second length L6 equals at least 100% of the first length.
  • second tether 256 is configured so as to define an anchor- . fixing loop 266, which passes through a corresponding interface (e.g., defined by struts of the stent) on first venous tissue anchor 30, so as to connect (e.g., permanently fix) the second tether to the first venous tissue anchor.
  • first tether 254 is configured so as to define one or both of anchor-fixing loops 268A and 268B, which pass through corresponding interfaces on second and third atrial tissue anchors 40 and 42, respectively, so as to connect (e.g., permanently fix) the first tether to the second and third atrial tissue anchors, respectively.
  • tether 256 comprises two separate sections 256A and
  • pulley 250 comprises a loop 252, through which first tether 254 is slidably moveable.
  • a coefficient of kinetic friction between the first tether and the loop is less than 0.5, such as less than 0.2, e.g., less than 0.1.
  • loop 252 comprises a closed loop; in other words, the ends of the loop are joined together.
  • loop 252 comprises an open loop; both ends of the cord that defines the loop are connected (e.g., permanently fixed) to first venous tissue anchor 30, but not to one another.
  • pulley 250 comprises a flexible longitudinal member that is connected (e.g., permanently fixed) to the first venous tissue anchor 30 at two points along the flexible longitudinal member, so as to define loop 252 longitudinally between the two points.
  • pulley 250 comprises ring 60, through which first tether 254 is slidably moveable.
  • a coefficient of kinetic friction between first tether 254 and ring 60 is less than 0.5, such as less than 0.2, e.g., less than 0.1.
  • pulley 250 comprises wheel 62 on an axle that supports movement of first tether 254 along the wheel's circumference. Wheel 62 typically is shaped so as to define a groove between two flanges around its circumference, as is well-known in the pulley art.
  • Pulley 250 may alternatively comprise an eyelet or a roller, such as described hereinabove with reference to Figs. 4 and 5A-B.
  • Figs. 8A-H are schematic illustrations of implantations of valve-tensioning implant system 220, in accordance with respective applications of the present invention.
  • the implantations are typically performed transvascularly, such as described hereinabove with reference to Figs. 3A-0.
  • First venous tissue anchor 30 is implanted at first site 89 in a vein selected from the group of veins consisting of: superior vena cava 110 (as shown, for example, in Figs. 8C-D), inferior vena cava 80 (as shown, for example, in Figs. 8A-B and 8H), and coronary sinus 115, as shown, for example, in Figs. 8E-G).
  • first venous tissue anchor 30 comprises intraluminal stent 46
  • the stent is expanded in the selected vein in order to anchor the stent to the wall of the vein by the outward radial force applied by the stent.
  • Second and third atrial tissue anchors 40 and 42 are implanted at respective different second atrial sites 290 and 292, each of which sites is selected from the group of sites consisting of: annulus 83 of tricuspid valve 78, and a wall of right atrium 81 above annulus 83.
  • second and third atrial tissue anchors 40 and 42 comprise respective helical tissue- coupling elements 48A and 48B, the helical tissue-coupling elements are rotated into tissue at the sites, respectively.
  • Pulley system 244 is implanted, locking mechanism 55, if provided, is attached, and a size of a tricuspid orifice is reduced by tensioning second tether 256, which also tensions first tether 254, so as to reduce regurgitation.
  • Fig. 8A shows the pulley system before the locking mechanism has been attached and the tethers have been tensioned
  • Fig. 8B shows the pulley system after the locking mechanism is attached and the tethers have been tensioned.
  • first, second, and third sites 89, 290, and 292, and of first, second, and third tissue anchors 30, 40, and 42 are to be understood only as convenient references to distinguish the sites and anchors from one another, and are not to be understood as implying or requiring any order of implantation or of other properties of the sites or anchors.
  • Pulley system 244 enables the controlled, uneven distribution of forces on tissue at first, second, and third implantation sites 89, 290, and 292.
  • a force vector V7 on the tissue at first implantation site 89 which is connected (e.g., permanently fixed) to pulley 250 by first venous tissue anchor 30, equals the vector sum of force vectors V8 and V9 acting on tissue at second and third implantation sites 290 and 292, respectively, which are connected (e.g., permanently fixed) to first tether 254 by second and third atrial tissue anchors 40 and 42, respectively.
  • the forces acting on first implantation site 89 (to which the pulley is fixed) is less than the forces acting on second and third implantation site 290 and 292.
  • This controlled distribution of forces may be particularly beneficial if, for example:
  • second implantation site 290 or third implantation site 292 is located in a region of tissue which is thicker or stronger than first implantation site 89.
  • tissue of the septum between the ventricles is thicker and stronger than the vena cava wall;
  • the anchoring mechanism of second and third tissue atrial anchors 40 and 42 anchors using mechanical purchase, e.g., using a helical anchor, while the anchoring mechanism of first venous tissue anchor 30 at first implantation site 89 is friction based, e.g., using an intraluminal stent; and/or
  • the force vectors acting on second and third implantation sites 290 and 292 are aligned along a preferable direction which causes constriction of the tricuspid valve in a more favorable manner than tensioning towards first implantation site 89.
  • the sites may be selected apply the maximum force on the implantation site that is desired to be moved.
  • the tissue anchors and pulley system 244 are arranged such that the vector sum of the forces on all of the implantation sites is zero, and the force vector on first implantation site 89 (to which the pulley is fixed) is the vector sum of the forces acting on second and third implantation sites 190 and 192.
  • the scalar force acting on second and third implantation sites 190 and 192 depends on an angle ⁇ (gamma) (labeled in Fig. 7) formed by first tether 254 at pulley 250, and may be expressed by Equation 1, described above with reference to Fig. 1, mutatis mutandis.
  • the force acting on first implantation site 89 (to which the pulley is fixed) is less than each of the forces acting on second and third implantation sites 290 and 292; at an angle ⁇ (gamma) of 120 degrees, all forces are approximately equal. As the angle increases and approximates 180 degrees, the force on first implantation site 89 is reduced to almost zero, although such an angle is not achievable in practice. For example, when angle ⁇ (gamma) is 140 degrees, the force at first implantation site 89 is only approximately 68% of the force acting on each of second and third implantation sites 190 and 192.
  • the force at first implantation site 89 is further reduced to approximately 35% of the force acting on each of second and third implantation sites 190 and 192.
  • the surgeon positions the tissue anchors and pulley system 144 such that two longitudinal portions 258A and 258B (labeled in Fig. 7) of first tether 254 adjacent to and on opposite sides of pulley 250 define an angle ⁇ (gamma) therebetween, typically of between 120 and 180 degrees, such as between 135 and 175 degrees, typically as close as possible to 180 degrees.
  • second and third implantation sites 290 and 292 are located within 1 cm of the site on the annulus that circumferentially corresponds to the respective anatomical marker.
  • the direction of the 1 cm from the site may be either circumferentially around the annulus, up the wall of right atrium 81 above annulus 83, or a combination of circumferentially around the annulus and up the wall of the atrium.
  • an implantation method comprises implanting first venous tissue anchor 30 at first implantation site 89 in inferior vena cava 80.
  • second atrial tissue anchor 40 is implanted at second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 112.
  • third atrial tissue anchor 42 is implanted at third implantation site 292 which is located within 1 cm of a site on the annulus that circumferentially corresponds to septoanterior commissure 114.
  • third atrial tissue anchor is implanted at third implantation site 292 which is located within 1 cm of a site on the annulus that circumferentially corresponds to circumferential middle 93 of septal leaflet 82.
  • the implantation method comprises implanting first venous tissue anchor 30 at first implantation site 89 in superior vena cava 1 10.
  • third atrial tissue anchor 42 is implanted at third implantation site 292 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 1 12.
  • second atrial tissue anchor 40 is implanted at second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to septoanterior commissure 1 14.
  • second atrial tissue anchor 40 is implanted at second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to circumferential middle 93 of septal leaflet 82.
  • the implantation method comprises implanting first venous tissue anchor 30 at first implantation site 89 in the coronary sinus.
  • third atrial tissue anchor 42 is implanted at third implantation site 292 which is located within 1 cm of a site on the annulus that circumferentially corresponds to anteroposterior commissure 112.
  • second atrial tissue anchor 40 is implanted at second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to septoanterior commissure 114.
  • second atrial tissue anchor 40 is implanted at second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to of circumferential middle 93 of septal leaflet 82.
  • second implantation site 290 which is located within 1 cm of a site on the annulus that circumferentially corresponds to of circumferential middle 93 of septal leaflet 82.
  • a valve- tensioning implant system 20, 220 is provided, which comprises first, second, and third tissue anchors 30, 40, and 42.
  • the yalve-tensioning implant comprises exactly three tissue anchors, which consist of first, second, and third tissue anchors 30, 40, and 42.
  • First tissue anchor 30 is not necessarily a venous tissue anchor.
  • Valve-tensioning implant system 20, 220 further comprises pulley system 44, 244, which comprises:
  • first tether 54, 254 which (a) is connected (e.g., permanently fixed) to second and third tissue anchors 40 and 42, (b) is moveable through pulley 50, 250, and (c) has a first length, measured between second and third tissue anchors 40 and 42, of at least 15 mm; and
  • FIGS. 9A and 9B are schematic illustrations of a delivery system comprising a multiple-anchor delivery tool 300, in accordance with respective applications of the present invention.
  • Multiple-anchor delivery tool 300 is used to sequentially deliver and implant two or more tissue anchors of an implant 310.
  • Implant 310 comprises: ⁇ at least first and second tissue anchors 340 and 342, which comprise (a) first and second helical tissue-coupling elements 48A and 48B, respectively, and (b) first and second heads 370A and 370B, respectively, which comprise first and second tether interfaces 380A and 380B; and
  • a tether 382 which is connected (e.g., permanently fixed) to first tether interface 380A, and coupled to second tether interface 380B (optionally slidably coupled to second tether interface 380B, such that the tether slidably passes through the second tether interface).
  • first tissue anchor 340 comprises first tissue anchor 40, second tissue anchor 140, or second tissue anchor 42, described hereinabove.
  • second tissue anchor 342 comprises first tissue anchor 40, second tissue anchor 140, or second tissue anchor 42, described hereinabove.
  • first tether interface 380A is rotatable with respect to first tissue-coupling element 48A
  • second tether interface 380B is rotatable with respect to first tissue-coupling element 48B .
  • implant 310 comprises a male coupling 480 of a first flexible-longitudinal-member-coupling element 482 of an intraluminal locking mechanism 484 which is connected to a female coupling during the implantation procedure, such as in order to allow implantation of the third tissue anchor with a separate catheter delivery system, such as described in above-mentioned US Patent Application Publication 2013/0018459, for example with reference to Figs. 25-26 thereof.
  • implant 310 comprises pulley 250, described hereinabove with reference to Figs. 7-8H.
  • the pulley may be connected to first flexible-longitudinal-member-coupling element 482.
  • pulley 250 is shown comprising ring 60, described hereinabove with reference to Fig. 2C, the pulley may alternatively comprise another of the pulleys described herein, including those described with reference to Fig. 2A or 2D.
  • Multiple-anchor delivery tool 300 comprises a catheter shaft 400 having proximal and distal ends 410 and 412.
  • First and second tissue anchors 340 and 342 are initially removably positioned in catheter shaft 400 at first and second longitudinal locations 414 and 416, respectively.
  • First longitudinal location 414 is more distal than second longitudinal location 416.
  • the tissue anchors are initially positioned in the desired sequence of deployment in the catheter shaft, with the first anchor to be deployed positioned more distally than the subsequent anchor(s) to be deployed.
  • the tissue anchors are interconnected by tether 382.
  • Multiple-anchor delivery tool 300 further comprises first and second torque cables
  • first torque cable 420 and 422 which (a) are removably coupled to first and second heads 370A and 370B, respectively, (b) extend within catheter shaft 400 proximally from first and second heads 370A and 370B, respectively, and (c) transmit torque when rotated, for rotating tissue- coupling elements 48A and 48B, respectively, into tissue.
  • the torque cables additionally transmit axial force, to enable pushing of the tissue-coupling elements 48A and 48B into the tissue as they are rotated.
  • a portion 430 of first torque cable 420 is initially removably positioned alongside second tissue anchor 342 in catheter shaft 400.
  • each anchor is separately connected to a control handle 470 by its own torque cable, which allows full and separate control of deployment of each anchor by an operator of the multiple-anchor delivery tool.
  • implant 310 comprises one or more additional tissue anchors
  • tool 300 correspondingly comprises one or more additional torque cables, removably coupled to the tissue-coupling elements, as described herein.
  • additional tissue anchors are initially removably positioned in catheter shaft 400 proximal to second longitudinal location 416.
  • implant 310 may further comprise a third tissue anchor, which comprises (a) a third helical tissue-coupling elements, and (b) a third head, which comprises a third tether interface; the tether is coupled to (e.g., slidably coupled to) the third tether interface; the third tissue anchor is removably positioned in catheter shaft 400 at a third longitudinal location that is more proximal than second longitudinal location 416; and multiple-anchor delivery tool 300 further comprises a third torque cable, which (a) is removably coupled to the third head, (b) extends within the catheter shaft proximaliy from the third head, and (c) transmits torque when rotated, wherein a portion of the second torque cable is removably positioned alongside the third tissue anchor in the catheter shaft.
  • a third tissue anchor which comprises (a) a third helical tissue-coupling elements, and (b) a third head, which comprises a third tether interface; the tether is coupled to (e.g.,
  • first torque cable 420 is shaped so as to define a lumen 440 therethrough, and multiple-anchor delivery tool 300 further comprises a sharpened wire 442, which removably passes through lumen 440.
  • a distal end of first torque cable 420 comprises a distal coupling element 450, which is configured to be removably coupled to a corresponding proximal coupling element 452 defined by a proximal portion of first head 370A.
  • Distal and proximal coupling elements 450 and 452 are shaped so as to define corresponding interlocking surfaces, such that the coupling elements interlock, thereby mating the coupling elements to one another.
  • Head 370A including proximal coupling element 452, is shaped so as to define a first longitudinal channel 456 at least partially therethrough (typically entirely therethrough), which channel is coaxial with head 370A.
  • Distal coupling element 450 is shaped so as to define a second longitudinal channel 458 therethrough, which is coaxial with lumen 440 of first torque cable 420.
  • First and second channels 456 and 458 are radially aligned with one another. When a portion of sharpened wire 442 is positioned in these channels, the sharpened wire prevents decoupling of distal coupling element 450 from proximal coupling element 452. Upon removal of sharpened wire 442 from channels 456 and 458 and the coupling elements 450 and 452, the coupling elements are free to be decoupled from one another.
  • sharpened wire 442 is shaped so as to define a sharp distal tip 460.
  • first tissue-coupling element 48A typically is helical, and sharpened wire 442 is initially removably positioned within a channel defined by the helix. As tissue-coupling element 48A is screwed into tissue, sharpened wire 442 penetrates and advances into the tissue along with the anchor to a certain depth in the tissue. For some applications, when the shaft penetrates to the certain depth, the sharpened wire is withdrawn slightly. Typically, after tissue-coupling element 48A has been fully implanted, sharpened wire 442 is withdrawn entirely from the tissue, and removed from the patient's body.
  • the sharp distal tip of sharpened wire 442 is inserted into the tissue slightly, even before insertion of tissue-coupling element 48A, in order to prevent sliding of the tissue-coupling element on the surface of the tissue before commencement of insertion of the tissue-coupling element into the tissue.
  • sharpened wire 442 is withdrawn proximally from the channel of tissue-coupling element 48A and from channels 456 and 458 of distal and proximal coupling elements 450 and 452, thereby decoupling the coupling elements from one another, and decoupling first torque cable 420 from head 370A.
  • sharpened wire442 typically remains within lumen 440 of first torque cable 420.
  • the decoupling of first torque cable 420 and head 370A is performed alternatively or additionally using techniques described in US Patent Application Publication 2012/0035712, which is assigned to the assignee of the present application and is incorporated herein by reference, such as with reference to Figs. 12A-C thereof.
  • Second torque cable 422 and second tissue anchor 342 similarly comprise the above-mentioned elements (e.g., the sharpened wire and coupling elements), and are similarly configured, as do any additional torque cables and tissue anchors that may be provided, as described above.
  • Multiple-anchor delivery tool 300 further comprises control handle 470, which is configured to control the deployment of the tissue anchors, by rotating the torque cables, distally advancing the anchors through catheter shaft 400, and proximally withdrawing the sharpened wire and torque cables.
  • Control handle 470 may implement features of handle portion 1004, described with reference to Fig. 1 1C of above-mentioned US Patent Application Publication 2012/0035712, mutatis mutandis.
  • FIGs. lOA-C are schematic illustrations of a deployment method using multiple-anchor delivery tool 300, in accordance with an application of the present invention. This method may be used to deploy first tissue anchor 40, second tissue anchor 140, and/or second tissue anchor 42, described hereinabove, or other tissue anchors.
  • Figs. lOA-C illustrate the implantation of the configuration of implant 310 shown in Fig. 9B, the same techniques can be used for the implantation of the configuration shown in Fig. 9A.
  • Catheter shaft 400 is typically advanced trans vascularly, using a delivery system comprising one or more catheters introduced with the aid of a guidewire, through vasculature of the subject, such as (a) via the femoral vein, through inferior vena cava 80, and into a right atrium 81, (b) via the basilic vein, through the subclavian vein through superior vena cava 110, and into right atrium 81, or (c) via the external jugular vein, through the subclavian vein through superior vena cava 110, and into right atrium 81.
  • the procedure is typically performed with the aid of imaging, such as fluoroscopy, transesophageal echo, and/or echocardiography.
  • the procedure may be performed using techniques described in US Patent Application Publication 2012/0035712, which is assigned to the assignee of the present application and is incorporated herein by reference, with reference to Figs. 1A-D thereof, mutatis mutandis.
  • Distal end 412 of catheter shaft 400 of multiple-anchor delivery tool 300 is advanced into the body of a subject, while (a) first and second tissue anchors 340 and 342 are removably positioned in catheter shaft 400 at first and second longitudinal locations 414 and 416, respectively, first longitudinal location 414 more distal than second longitudinal location 416. Portion 430 of first torque cable 420 is removably positioned alongside second tissue anchor 342 in catheter shaft 400.
  • catheter shaft 400 does not need to be withdrawn and reintroduced from the body during the implantation procedure.
  • first tissue anchor 340 is implanted into tissue 500 of the subject (e.g., cardiac muscle tissue, such as atrial tissue) by rotating first torque cable 420, using control handle 470, and, typically pushing distally on the torque cable.
  • tissue 500 of the subject e.g., cardiac muscle tissue, such as atrial tissue
  • first torque cable 420 is decoupled from first tissue anchor 340, such as by proximally withdrawing sharpened wire 442, as described hereinabove with reference to Figs. 9A-B.
  • First torque cable 420 is typically further proximally withdrawn in catheter shaft 400 (not shown), and optionally withdrawn out of the proximal end of the catheter shaft.
  • second tissue anchor 342 is distally advanced in catheter shaft 400, and implanted into tissue 500 by rotating second torque cable 422.
  • the second torque cable is decoupled from second tissue anchor 342 (not shown).
  • First and second tissue anchors 340 and 342 remain implanted in tissue 500, connected by tether 382, with the pulley freely movable on it.
  • Pulley 250 which extends distally from second tether interface 380B, may be tensioned so as to apply tension between the first and the second tissue anchors, as described hereinabove with reference to Figs. 8A-H.
  • pulley 250 may be removably connected to a flexible longitudinal guide member 390 by first flexible- longitudinal-member-coupling element 482, which may be coupled to the female part of the locking mechanism using a separate catheter delivery system containing first venous tissue anchor 30, such as described in above-mentioned US Patent Application Publication 2013/0018459, for example with reference to Figs. 23-26 thereof, mutatis mutandis (in which flexible longitudinal guide member 2616 corresponds to flexible longitudinal guide member 390 of the present application).
  • FIGs. 11A-D are schematic illustrations of a delivery system comprising multiple-anchor delivery tools 600A, 600B, 600C, and 600D, respectively, in accordance with respective applications of the present invention.
  • Multiple-anchor delivery tools 600 are used to sequentially deliver and implant one or more helical tissue anchors 640 and an intraluminal stent anchor 646 of an implant, such as one of the implants described hereinabove.
  • multiple-anchor delivery tools 600 may be used alone or in combination with multiple-anchor delivery tool 300, described hereinabove with reference to Figs. 9A-B.
  • Each of multiple-anchor delivery tools 600 typically comprises an inner stent- deployment shaft 650, a distal tubular tip element 652, an outer shaft 654, and an outer delivery catheter 656.
  • Stent anchor 646 is initially removably disposed surrounding a longitudinal portion of inner stent-deployment shaft 650 and within distal tubular tip element 652. With the stent anchor thus positioned, distal tubular tip element 652 is pushed into coronary sinus 115. Distal advancement of distal tubular tip element 652 with respect to inner stent-deployment shaft 650 releases stent anchor 646, which typically self-expands upon release.
  • the distal tubular tip element may be advanced distally by distally advancing a pusher rod 658 that passes through a channel of inner stent-deployment shaft 650 and is coupled to the distal tubular tip element (typically to a distal end thereof, within the tip element).
  • Inner stent-deployment shaft 650 is slidably disposed within a channel of outer shaft 654, which itself is advanceable within a channel of outer delivery catheter 656.
  • pusher rod 658 and a distal portion of tip element 652 typically are shaped so as to define a channel therethrough, through which a guidewire 670 passes.
  • Multiple-anchor delivery tool 600A is configured to deploy a helical tissue anchor 640 and stent anchor 646.
  • Multiple-anchor delivery tool 600A is capable of deploying either the helical tissue anchor or the stent anchor first.
  • Helical tissue anchor 640 is deployed using an anchor-deployment shaft 660, which passes through outer shaft 654, and typically exits the outer shaft through a lateral opening 662.
  • Stent anchor 646 and helical tissue anchor 640 are tensioned to a stent venous tissue anchor (such as first venous tissue anchor 30) in SVC 110 or IVC 80, such as described hereinabove with reference to Figs. 3L and 3M (the configuration described with reference to Fig. 6F is also similar).
  • multiple-anchor delivery tool 600A is used as described hereinbelow with reference to Figs. 12A-C.
  • Multiple-anchor delivery tool 600B is configured to deploy a female coupling element 680 and stent anchor 646.
  • Stent anchor delivery tool 600B is capable of deploying stent anchor and connecting it to the male locking mechanism of multiple anchor deploying system such as described in Fig. 9A.
  • Female coupling element 680 is deployed using shaft 660, which passes through outer shaft .654, and typically exits the outer shaft through a lateral opening 662. The stent anchor and the female coupling element are tethered together by a textile band.
  • Female coupling element 680 may be connected to a male coupling element during the implantation procedure.
  • the female and male coupling elements may be components of intraluminal locking mechanism 55, described hereinabove with reference to Figs.
  • male and female coupling elements may be connected using techniques described in US Patent Application Publication 2013/0018459, such as with reference to Figs. 20-32 thereof.
  • Female coupling element 680 is then used to tether the first two helical tissue anchors, such as described hereinabove with reference to Fig. 9A, to a coronary sinus stent.
  • the coronary sinus stent is then pushed forward into the coronary stent, thereby tensioning the tether system.
  • Multiple-anchor delivery tool 600C is configured to deploy two helical tissue anchors 640A and 640B, and stent anchor 646.
  • multiple-anchor delivery tool 600C first deploys the two helical tissue anchors, using respective anchor-deployment shafts 660A and 660B, both of which pass through outer shaft 654, and typically exit the outer shaft through respective lateral openings 662 A and 662B. Thereafter, multiple-anchor delivery tool 600C is used to push distal tubular tip element 652 into coronary sinus 115, with stent anchor 646 removably disposed surrounding the longitudinal portion of inner stent-deployment shaft 650 and within distal tubular tip element 652.
  • Distal tubular tip element 652 is advanced in the coronary sinus until sufficient tension has been applied to the tethers and thus to the valve.
  • multiple-anchor delivery tool 600C may be used to achieve the deployment configurations described hereinabove with reference to Figs. 3J, 3K, and 3N (Figs. 6H, 61, 8E, 8F, and 8G also show similar configurations).
  • the pulley may be connected to the appropriate tissue anchor of the system.
  • Multiple-anchor delivery tool 600D is configured to deploy a helical tissue anchor 640 and stent anchor 646.
  • Multiple-anchor delivery tool 600D is capable of deploying either the helical tissue anchor or the stent anchor first.
  • Stent anchor 646 is connected to first venous tissue anchor 30 in SVC 110 or IVC 80, via a tether, such as using mating techniques described in US Patent Application Publication 2013/0018459, as described hereinabove.
  • multiple-anchor delivery tool 600D is used to achieve the deployment configurations described hereinabove with reference to Figs. 3L, 3M, and 6F. Reference is now made to Figs.
  • FIGS. 12A-C are schematic illustrations of the deployment of a valve-tensioning implant system using multiple-anchor delivery tool 600A, in accordance with an application of the present invention. Similar techniques can be used for deployment of a valve-tensioning implant using multiple-anchor delivery tools 600B, 600C, and 600D, mutatis mutandis.
  • multiple-anchor delivery tool 600A is used to first deploy stent anchor 646 in coronary sinus 115, as described hereinabove with reference to Figs. 11A-D.
  • multiple-anchor delivery tool 600A is then used to deploy helical tissue anchor 640 on the annulus.
  • helical tissue anchor 640 is deployed before stent anchor 646.
  • a venous tissue anchor 30 is deployed in SVC 110 and tension is applied on a first tether 740 connecting venous tissue anchor 30 and stent anchor 646 to a pulley 750, which is connected by a second tether 742 to helical tissue anchor 640.
  • multiple-anchor delivery tool 300 sets forth exemplary uses of multiple-anchor delivery tool 300, described hereinabove with reference to Figs. 9A-B, and/or multiple-anchor delivery tools 600A, 600B, 600C, or 600D, to achieve some of the deployment configurations described hereinabove.
  • multiple-anchor delivery tools 600A, 600B, 600C, or 600D may optionally be used to achieve others of the deployment configurations described hereinabove, mutatis mutandis.
  • the stents described herein may be used as one or more of the stents described in the above-listed applications, in combination with the other techniques described therein. It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne un implant de tensionnement de valvule comprenant un premier point d'ancrage de tissu veineux (30) qui est conçu pour être implanté dans une veine sélectionnée parmi le groupe de veines composé de: une veine cave supérieure (110), une veine cave inférieure (80) et un sinus coronaire (115); exactement deux points d'ancrage de tissu auriculaire, qui sont composés de deuxième et troisième points d'ancrage de tissu auriculaire (40, 42); et un système de poulie (44). Le système de poulie (44) comprend une poulie (50), qui est raccordée au deuxième point d'ancrage de tissu auriculaire (40); et un câble (54), lequel (a) est raccordé au premier point d'ancrage de tissu veineux (30) et au troisième point d'ancrage de tissu auriculaire (42), (b) est mobile à travers la poulie (50) et (c) présente une longueur d'au moins 30 mm mesurée entre le premier point d'ancrage de tissu veineux et le troisième point d'ancrage de tissu auriculaire (30, 42). D'autres modes de réalisation sont également décrits.
EP14802711.3A 2013-10-30 2014-10-28 Système de tension à multiples points d'ancrage Withdrawn EP3062709A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897509P 2013-10-30 2013-10-30
PCT/IB2014/002351 WO2015063580A2 (fr) 2013-10-30 2014-10-28 Système de tension à multiples points d'ancrage

Publications (1)

Publication Number Publication Date
EP3062709A2 true EP3062709A2 (fr) 2016-09-07

Family

ID=51951833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14802711.3A Withdrawn EP3062709A2 (fr) 2013-10-30 2014-10-28 Système de tension à multiples points d'ancrage

Country Status (3)

Country Link
US (1) US10039643B2 (fr)
EP (1) EP3062709A2 (fr)
WO (1) WO2015063580A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007043830A1 (de) 2007-09-13 2009-04-02 Lozonschi, Lucian, Madison Herzklappenstent
WO2011072084A2 (fr) 2009-12-08 2011-06-16 Avalon Medical Ltd. Dispositif et système de remplacement de valvule mitrale transcathéter
US9307980B2 (en) 2010-01-22 2016-04-12 4Tech Inc. Tricuspid valve repair using tension
US10058323B2 (en) 2010-01-22 2018-08-28 4 Tech Inc. Tricuspid valve repair using tension
US8475525B2 (en) 2010-01-22 2013-07-02 4Tech Inc. Tricuspid valve repair using tension
US9480559B2 (en) 2011-08-11 2016-11-01 Tendyne Holdings, Inc. Prosthetic valves and related inventions
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
US8961594B2 (en) 2012-05-31 2015-02-24 4Tech Inc. Heart valve repair system
WO2014022124A1 (fr) 2012-07-28 2014-02-06 Tendyne Holdings, Inc. Conceptions multi-composantes améliorées pour dispositif de récupération de valve cardiaque, structures d'étanchéité et ensemble stent
WO2014021905A1 (fr) 2012-07-30 2014-02-06 Tendyne Holdings, Inc. Systèmes et procédés d'administration améliorée pour valvules prothétiques transcathéter
CN105007832B (zh) 2013-01-09 2018-01-23 4科技有限公司 组织锚状物设备
WO2014141239A1 (fr) 2013-03-14 2014-09-18 4Tech Inc. Endoprothèse ayant une interface de câble d'attache
US10463489B2 (en) 2013-04-02 2019-11-05 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US11224510B2 (en) 2013-04-02 2022-01-18 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US10478293B2 (en) 2013-04-04 2019-11-19 Tendyne Holdings, Inc. Retrieval and repositioning system for prosthetic heart valve
US9610159B2 (en) 2013-05-30 2017-04-04 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
CA2914856C (fr) 2013-06-25 2021-03-09 Chad Perrin Caracteristiques de gestion de thrombus et de conformite structurelle pour valvules cardiaques prothetiques
WO2015017689A1 (fr) 2013-08-01 2015-02-05 Robert Vidlund Dispositifs et procédés d'ancrage épicardique
WO2015058039A1 (fr) 2013-10-17 2015-04-23 Robert Vidlund Appareil et procedes d'alignement et de deploiement de dispositifs intracardiaques
CA2924389C (fr) 2013-10-28 2021-11-09 Tendyne Holdings, Inc. Valvule cardiaque prothetique, et ses systemes et procedes de pose
US9526611B2 (en) 2013-10-29 2016-12-27 Tendyne Holdings, Inc. Apparatus and methods for delivery of transcatheter prosthetic valves
US10052095B2 (en) 2013-10-30 2018-08-21 4Tech Inc. Multiple anchoring-point tension system
US10022114B2 (en) 2013-10-30 2018-07-17 4Tech Inc. Percutaneous tether locking
WO2015063580A2 (fr) 2013-10-30 2015-05-07 4Tech Inc. Système de tension à multiples points d'ancrage
WO2015120122A2 (fr) 2014-02-05 2015-08-13 Robert Vidlund Appareil et procédés pour la mise en place d'une valve mitrale prothétique par l'artère fémorale
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
JP6865037B2 (ja) 2014-03-10 2021-04-28 テンダイン ホールディングス，インコーポレイテッド 人工僧帽弁を位置決めするため及び人工僧帽弁のテザーの荷重を監視するためのデバイス及び方法
EP3157607B1 (fr) 2014-06-19 2019-08-07 4Tech Inc. Serrage de tissu cardiaque
WO2016087934A1 (fr) 2014-12-02 2016-06-09 4Tech Inc. Ancrages de tissu excentrés
AU2016205371B2 (en) 2015-01-07 2019-10-10 Tendyne Holdings, Inc. Prosthetic mitral valves and apparatus and methods for delivery of same
AU2016215197B2 (en) 2015-02-05 2020-01-02 Tendyne Holdings Inc. Expandable epicardial pads and devices and methods for their delivery
AU2016248314B2 (en) 2015-04-16 2020-05-21 Tendyne Holdings, Inc. Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves
CN110755176B (zh) * 2015-05-28 2022-07-08 4科技有限公司 用于在约束状态下在部署工具内递送的装置
US10327894B2 (en) 2015-09-18 2019-06-25 Tendyne Holdings, Inc. Methods for delivery of prosthetic mitral valves
JP2018535754A (ja) 2015-12-03 2018-12-06 テンダイン ホールディングス，インコーポレイテッド 人工僧帽弁用のフレーム特徴
AU2016380259B2 (en) 2015-12-28 2020-10-22 Tendyne Holdings, Inc. Atrial pocket closures for prosthetic heart valves
WO2017117370A2 (fr) * 2015-12-30 2017-07-06 Mitralign, Inc. Système et procédé de réduction de régurgitation tricuspide
US10470877B2 (en) 2016-05-03 2019-11-12 Tendyne Holdings, Inc. Apparatus and methods for anterior valve leaflet management
US20200146854A1 (en) 2016-05-16 2020-05-14 Elixir Medical Corporation Methods and devices for heart valve repair
EP3468480B1 (fr) 2016-06-13 2023-01-11 Tendyne Holdings, Inc. Administration séquentielle de valvule mitrale prothétique en deux parties
EP3478224B1 (fr) 2016-06-30 2022-11-02 Tendyne Holdings, Inc. Valves cardiaques prothétiques et appareil associés de mise en place
US11065116B2 (en) 2016-07-12 2021-07-20 Tendyne Holdings, Inc. Apparatus and methods for trans-septal retrieval of prosthetic heart valves
JP6632047B2 (ja) 2016-08-18 2020-01-15 ４テック インコーポレイテッド 囲心腔への挿入のための可撓性先端部を有する組織アンカー
US11083580B2 (en) 2016-12-30 2021-08-10 Pipeline Medical Technologies, Inc. Method of securing a leaflet anchor to a mitral valve leaflet
US10925731B2 (en) 2016-12-30 2021-02-23 Pipeline Medical Technologies, Inc. Method and apparatus for transvascular implantation of neo chordae tendinae
US9877833B1 (en) 2016-12-30 2018-01-30 Pipeline Medical Technologies, Inc. Method and apparatus for transvascular implantation of neo chordae tendinae
CN110381895B (zh) * 2017-02-08 2020-05-26 4科技有限公司 植入式测力计
JP6718189B2 (ja) * 2017-02-08 2020-07-08 ４テック インコーポレイテッド 心臓埋め込みにおける埋め込み後の張力付与
WO2018160456A1 (fr) 2017-03-01 2018-09-07 4Tech Inc. Réglage de la tension après implantation d'implants cardiaques
US20180353297A1 (en) 2017-06-08 2018-12-13 4Tech Inc. Tissue Anchor with Tether Stop
WO2019013994A1 (fr) 2017-07-10 2019-01-17 4Tech Inc. Ancrages de tissu dotés d'éléments de support de charge
EP3651695B1 (fr) 2017-07-13 2023-04-19 Tendyne Holdings, Inc. Valves cardiaques prothétiques et appareil associés de mise en place
CN111031967B (zh) 2017-08-28 2022-08-09 坦迪尼控股股份有限公司 具有系带连接特征的人造心脏瓣膜
WO2019074815A1 (fr) 2017-10-10 2019-04-18 4Tech Inc. Système d'ancrage à distribution de force
JP2020528809A (ja) 2017-10-31 2020-10-01 ４テック インコーポレイテッド 止血造作部を有する組織アンカー
JP2020537563A (ja) 2018-02-09 2020-12-24 ４テック インコーポレイテッド 円錐台状止血用シール要素
EP3720363A1 (fr) 2018-08-07 2020-10-14 4 Tech Inc. Mise sous tension post-implantation dans des implants cardiaques
JP2022513793A (ja) 2018-12-12 2022-02-09 パイプライン メディカル テクノロジーズ， インコーポレイテッド 僧帽弁腱索修復のための方法及び装置
WO2020139776A1 (fr) 2018-12-24 2020-07-02 4Tech Inc. Ancrages de tissus à verrouillage automatique
KR102156647B1 (ko) * 2019-01-21 2020-09-16 (주) 타우피엔유메디칼 조립형 삼첨판막 역류증 시술용 기구
EP3831343B1 (fr) 2019-12-05 2024-01-31 Tendyne Holdings, Inc. Ancrage tressé pour valvule mitrale
US11648114B2 (en) 2019-12-20 2023-05-16 Tendyne Holdings, Inc. Distally loaded sheath and loading funnel
US11951002B2 (en) 2020-03-30 2024-04-09 Tendyne Holdings, Inc. Apparatus and methods for valve and tether fixation
US11395910B2 (en) 2020-05-20 2022-07-26 Rainbow Medical Ltd. Passive pump
IT202000012562A1 (it) 2020-05-27 2021-11-27 Milano Politecnico Dispositivo e assieme per riparare una valvola cardiaca
WO2022039853A1 (fr) 2020-08-19 2022-02-24 Tendyne Holdings, Inc. Tampon apical entièrement transseptal doté d'une poulie pour la mise sous tension
US11357629B1 (en) 2021-10-25 2022-06-14 Rainbow Medical Ltd. Diastolic heart failure treatment

Family Cites Families (431)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214349A (en) 1978-11-30 1980-07-29 Midland-Ross Corporation Tie wrap
GB2084468B (en) 1980-09-25 1984-06-06 South African Inventions Surgical implant
IT1144379B (it) 1981-07-14 1986-10-29 Sorin Biomedica Spa Protesi valvolare cardiaca
US4444207A (en) 1981-10-19 1984-04-24 Cordis Corporation Method of anchoring a temporary cardiac pacing lead
US4405313A (en) 1982-01-29 1983-09-20 Sisley James R Figure-eight, dual-lumen catheter and method of using
US4493329A (en) 1982-08-19 1985-01-15 Lynn Crawford Implantable electrode having different stiffening and curvature maintaining characteristics along its length
US4532926A (en) 1983-06-20 1985-08-06 Ethicon, Inc. Two-piece tissue fastener with ratchet leg staple and sealable latching receiver
US4548202A (en) 1983-06-20 1985-10-22 Ethicon, Inc. Mesh tissue fasteners
US4741336A (en) 1984-07-16 1988-05-03 Ethicon, Inc. Shaped staples and slotted receivers (case VII)
US4625727A (en) 1985-01-24 1986-12-02 Leiboff Arnold R Anastomosis device with excisable frame
US4712549A (en) 1985-07-01 1987-12-15 Edward Weck & Co. Automatic hemostatic clip applier
US4853986A (en) 1986-01-02 1989-08-08 The Awareness Marketing Corporation Water level control
US4808157A (en) 1987-07-13 1989-02-28 Neuro Delivery Technology, Inc. Multi-lumen epidural-spinal needle
FI85223C (fi) 1988-11-10 1992-03-25 Biocon Oy Biodegraderande kirurgiska implant och medel.
US5336233A (en) 1989-01-26 1994-08-09 Chen Fusen H Anastomotic device
SE467459B (sv) 1990-09-25 1992-07-20 Allset Marine Lashing Ab Vridlaas foer hoernlaadorna till containrar
US5108420A (en) 1991-02-01 1992-04-28 Temple University Aperture occlusion device
CA2078530A1 (fr) 1991-09-23 1993-03-24 Jay Erlebacher Dispositif d'occlusion en cas de ponction percutanee arterielle et instrument permettant son insertion
US5330521A (en) 1992-06-29 1994-07-19 Cohen Donald M Low resistance implantable electrical leads
US5374286A (en) 1993-03-31 1994-12-20 Medtronic, Inc. Torque indicator for fixed screw leads
US6776754B1 (en) 2000-10-04 2004-08-17 Wilk Patent Development Corporation Method for closing off lower portion of heart ventricle
US5450860A (en) 1993-08-31 1995-09-19 W. L. Gore & Associates, Inc. Device for tissue repair and method for employing same
US5843120A (en) 1994-03-17 1998-12-01 Medinol Ltd. Flexible-expandable stent
AU3783195A (en) 1994-11-15 1996-05-23 Advanced Cardiovascular Systems Inc. Intraluminal stent for attaching a graft
US5904697A (en) 1995-02-24 1999-05-18 Heartport, Inc. Devices and methods for performing a vascular anastomosis
US6743198B1 (en) 1995-03-20 2004-06-01 Conticare Medical, Inc. Self-cleansing bladder drainage device
US5662683A (en) 1995-08-22 1997-09-02 Ortho Helix Limited Open helical organic tissue anchor and method of facilitating healing
ATE218052T1 (de) 1995-11-27 2002-06-15 Schneider Europ Gmbh Stent zur anwendung in einem körperlichen durchgang
US5957953A (en) 1996-02-16 1999-09-28 Smith & Nephew, Inc. Expandable suture anchor
US5776178A (en) 1996-02-21 1998-07-07 Medtronic, Inc. Medical electrical lead with surface treatment for enhanced fixation
US6402780B2 (en) 1996-02-23 2002-06-11 Cardiovascular Technologies, L.L.C. Means and method of replacing a heart valve in a minimally invasive manner
US6702846B2 (en) 1996-04-09 2004-03-09 Endocare, Inc. Urological stent therapy system and method
AU3186897A (en) 1996-05-08 1997-11-26 Salviac Limited An occluder device
US5948000A (en) 1996-10-03 1999-09-07 United States Surgical Corporation System for suture anchor placement
US6045497A (en) 1997-01-02 2000-04-04 Myocor, Inc. Heart wall tension reduction apparatus and method
US6406420B1 (en) 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6251109B1 (en) 1997-06-27 2001-06-26 Daig Corporation Process and device for the treatment of atrial arrhythmia
US6042606A (en) 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6027523A (en) 1997-10-06 2000-02-22 Arthrex, Inc. Suture anchor with attached disk
US6332893B1 (en) 1997-12-17 2001-12-25 Myocor, Inc. Valve to myocardium tension members device and method
US6193734B1 (en) 1998-01-23 2001-02-27 Heartport, Inc. System for performing vascular anastomoses
US6533807B2 (en) 1998-02-05 2003-03-18 Medtronic, Inc. Radially-expandable stent and delivery system
US20050021085A1 (en) 1998-05-11 2005-01-27 Surgical Connections, Inc. Surgical stabilizer devices and methods
US7063711B1 (en) 1998-05-29 2006-06-20 By-Pass, Inc. Vascular surgery
US6010113A (en) 1998-06-15 2000-01-04 Honeywell, Inc. Damper with fanning blades
US6206913B1 (en) 1998-08-12 2001-03-27 Vascular Innovations, Inc. Method and system for attaching a graft to a blood vessel
US20010049554A1 (en) 1998-11-18 2001-12-06 Carlos E. Ruiz Endovascular prosthesis and method of making
AU768150B2 (en) 1999-01-22 2003-12-04 W.L. Gore & Associates, Inc. A biliary stent-graft
US6298272B1 (en) 1999-03-29 2001-10-02 Cardiac Pacemakers, Inc. High impedance electrode tip with internal drug delivery capability
US7563267B2 (en) 1999-04-09 2009-07-21 Evalve, Inc. Fixation device and methods for engaging tissue
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
AU770243B2 (en) 1999-04-09 2004-02-19 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6273911B1 (en) 1999-04-22 2001-08-14 Advanced Cardiovascular Systems, Inc. Variable strength stent
US20050222665A1 (en) 1999-04-23 2005-10-06 Ernest Aranyi Endovascular fastener applicator
US6626899B2 (en) 1999-06-25 2003-09-30 Nidus Medical, Llc Apparatus and methods for treating tissue
SE514718C2 (sv) 1999-06-29 2001-04-09 Jan Otto Solem Anordning för behandling av bristande tillslutningsförmåga hos mitralisklaffapparaten
AU6178300A (en) 1999-08-09 2001-03-05 Salviac Limited An occluder with anchor
US6592609B1 (en) 1999-08-09 2003-07-15 Bonutti 2003 Trust-A Method and apparatus for securing tissue
ES2283316T3 (es) 1999-09-13 2007-11-01 Rex Medical, Lp Cierre vascular.
US6231561B1 (en) 1999-09-20 2001-05-15 Appriva Medical, Inc. Method and apparatus for closing a body lumen
US7615076B2 (en) 1999-10-20 2009-11-10 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US6626930B1 (en) 1999-10-21 2003-09-30 Edwards Lifesciences Corporation Minimally invasive mitral valve repair method and apparatus
AUPQ366099A0 (en) 1999-10-26 1999-11-18 Queensland University Of Technology Ortho paedic screw
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US6458153B1 (en) 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US7169187B2 (en) 1999-12-22 2007-01-30 Ethicon, Inc. Biodegradable stent
US6494908B1 (en) 1999-12-22 2002-12-17 Ethicon, Inc. Removable stent for body lumens
US6989028B2 (en) 2000-01-31 2006-01-24 Edwards Lifesciences Ag Medical system and method for remodeling an extravascular tissue structure
US6797002B2 (en) 2000-02-02 2004-09-28 Paul A. Spence Heart valve repair apparatus and methods
US6461336B1 (en) 2000-02-08 2002-10-08 LARRé JORGE CASADO Cardiological medical equipment
DE10010074B4 (de) 2000-02-28 2005-04-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung zur Befestigung und Verankerung von Herzklappenprothesen
US7993368B2 (en) 2003-03-13 2011-08-09 C.R. Bard, Inc. Suture clips, delivery devices and methods
US7347870B1 (en) 2000-05-25 2008-03-25 Bioring Sa Device for shrinking or reinforcing the heart valvular orifices
US7632303B1 (en) 2000-06-07 2009-12-15 Advanced Cardiovascular Systems, Inc. Variable stiffness medical devices
US6575976B2 (en) 2000-06-12 2003-06-10 Arthrex, Inc. Expandable tissue anchor
US7077861B2 (en) 2000-07-06 2006-07-18 Medtentia Ab Annuloplasty instrument
US6613078B1 (en) 2000-08-02 2003-09-02 Hector Daniel Barone Multi-component endoluminal graft assembly, use thereof and method of implanting
US7510572B2 (en) 2000-09-12 2009-03-31 Shlomo Gabbay Implantation system for delivery of a heart valve prosthesis
US20060106278A1 (en) 2004-05-14 2006-05-18 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of an adjustable bridge implant system
US8956407B2 (en) 2000-09-20 2015-02-17 Mvrx, Inc. Methods for reshaping a heart valve annulus using a tensioning implant
US6893459B1 (en) 2000-09-20 2005-05-17 Ample Medical, Inc. Heart valve annulus device and method of using same
US20080091264A1 (en) 2002-11-26 2008-04-17 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of magnetic tools
US6602288B1 (en) 2000-10-05 2003-08-05 Edwards Lifesciences Corporation Minimally-invasive annuloplasty repair segment delivery template, system and method of use
US6616684B1 (en) 2000-10-06 2003-09-09 Myocor, Inc. Endovascular splinting devices and methods
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
US7041097B1 (en) 2000-12-21 2006-05-09 Cardiac Pacemakers, Inc. System and method for accessing the coronary sinus
US6929660B1 (en) 2000-12-22 2005-08-16 Advanced Cardiovascular Systems, Inc. Intravascular stent
US6503259B2 (en) 2000-12-27 2003-01-07 Ethicon, Inc. Expandable anastomotic device
CN1529571A (zh) 2001-03-08 2004-09-15 ̩ 心房过滤器植入物
FR2822370B1 (fr) 2001-03-23 2004-03-05 Perouse Lab Endoprothese tubulaire comportant une bague deformable et necessaire d'intervention pour son implantation
US20090143808A1 (en) 2001-04-24 2009-06-04 Houser Russell A Guided Tissue Cutting Device, Method of Use and Kits Therefor
IL143007A0 (en) 2001-05-07 2002-04-21 Rafael Medical Technologies In Retrievable intravascular support structures
US6641597B2 (en) 2001-05-25 2003-11-04 Arthrex, Inc. Interference fit knotless suture anchor fixation
FR2826863B1 (fr) 2001-07-04 2003-09-26 Jacques Seguin Ensemble permettant la mise en place d'une valve prothetique dans un conduit corporel
DE60236093D1 (de) 2001-07-26 2010-06-02 Merit Medical Systems Inc Entfernbarer stent
US7288105B2 (en) 2001-08-01 2007-10-30 Ev3 Endovascular, Inc. Tissue opening occluder
US6997944B2 (en) 2001-08-13 2006-02-14 Advanced Cardiovascular Systems, Inc. Apparatus and method for decreasing stent gap size
EP1432369B1 (fr) 2001-08-31 2008-02-27 Mitral Interventions Appareil de reparation de valvule
US7338506B2 (en) 2001-09-05 2008-03-04 Caro Nicholas C Scleral clip and procedures for using same
US20060052821A1 (en) 2001-09-06 2006-03-09 Ovalis, Inc. Systems and methods for treating septal defects
US6893460B2 (en) 2001-10-11 2005-05-17 Percutaneous Valve Technologies Inc. Implantable prosthetic valve
US7144363B2 (en) 2001-10-16 2006-12-05 Extensia Medical, Inc. Systems for heart treatment
US6949122B2 (en) 2001-11-01 2005-09-27 Cardiac Dimensions, Inc. Focused compression mitral valve device and method
US8231639B2 (en) 2001-11-28 2012-07-31 Aptus Endosystems, Inc. Systems and methods for attaching a prosthesis within a body lumen or hollow organ
US20050177180A1 (en) 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US20030176914A1 (en) 2003-01-21 2003-09-18 Rabkin Dmitry J. Multi-segment modular stent and methods for manufacturing stents
US6976995B2 (en) 2002-01-30 2005-12-20 Cardiac Dimensions, Inc. Fixed length anchor and pull mitral valve device and method
US6793673B2 (en) 2002-12-26 2004-09-21 Cardiac Dimensions, Inc. System and method to effect mitral valve annulus of a heart
US6908478B2 (en) 2001-12-05 2005-06-21 Cardiac Dimensions, Inc. Anchor and pull mitral valve device and method
US7179282B2 (en) 2001-12-05 2007-02-20 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US6978176B2 (en) 2001-12-08 2005-12-20 Lattouf Omar M Treatment for patient with congestive heart failure
JP4230915B2 (ja) 2001-12-21 2009-02-25 シムチャ ミロ 輪状形成リング用移植システム
EP1458313B1 (fr) 2001-12-28 2010-03-31 Edwards Lifesciences AG Dispositif à mémoire retardée
US7048754B2 (en) 2002-03-01 2006-05-23 Evalve, Inc. Suture fasteners and methods of use
US6797001B2 (en) 2002-03-11 2004-09-28 Cardiac Dimensions, Inc. Device, assembly and method for mitral valve repair
US20090112052A1 (en) 2002-03-25 2009-04-30 Ams Research Corporation Implant Inserted Without Bone Anchors For Treatment of Urge Incontinence
CA2744868C (fr) 2002-05-08 2015-12-29 Cardiac Dimensions, Inc. Dispositif et procede permettant de modifier la forme d'un organe corporel
WO2003094795A1 (fr) 2002-05-10 2003-11-20 Cordis Corporation Procede de fabrication de dispositif medical comportant une membrane tubulaire a paroi mince sur un support structural
US7351256B2 (en) 2002-05-10 2008-04-01 Cordis Corporation Frame based unidirectional flow prosthetic implant
US20040117004A1 (en) 2002-05-16 2004-06-17 Osborne Thomas A. Stent and method of forming a stent with integral barbs
US7101395B2 (en) 2002-06-12 2006-09-05 Mitral Interventions, Inc. Method and apparatus for tissue connection
US9226825B2 (en) 2002-06-13 2016-01-05 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
IL150855A (en) 2002-07-22 2007-06-03 Leonid Monassevitch Intratubular anastomosis apparatus
US20040044364A1 (en) 2002-08-29 2004-03-04 Devries Robert Tissue fasteners and related deployment systems and methods
US8758372B2 (en) 2002-08-29 2014-06-24 St. Jude Medical, Cardiology Division, Inc. Implantable devices for controlling the size and shape of an anatomical structure or lumen
CO5500017A1 (es) 2002-09-23 2005-03-31 3F Therapeutics Inc Valvula mitral protesica
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
US8010207B2 (en) 2002-10-31 2011-08-30 Medtronic, Inc. Implantable medical lead designs
WO2004045378A2 (fr) 2002-11-15 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Procede et dispositif de reparation par catheter de valvules cardiaques
US7335213B1 (en) 2002-11-15 2008-02-26 Abbott Cardiovascular Systems Inc. Apparatus and methods for heart valve repair
US7485143B2 (en) 2002-11-15 2009-02-03 Abbott Cardiovascular Systems Inc. Apparatuses and methods for heart valve repair
US7175625B2 (en) 2002-11-25 2007-02-13 Triage Medical Soft tissue anchor and method of using same
US7108710B2 (en) 2002-11-26 2006-09-19 Abbott Laboratories Multi-element biased suture clip
US7608114B2 (en) 2002-12-02 2009-10-27 Gi Dynamics, Inc. Bariatric sleeve
US7837729B2 (en) 2002-12-05 2010-11-23 Cardiac Dimensions, Inc. Percutaneous mitral valve annuloplasty delivery system
US7037290B2 (en) 2002-12-16 2006-05-02 Medtronic, Inc. Multi-lumen steerable catheter
US7316710B1 (en) 2002-12-30 2008-01-08 Advanced Cardiovascular Systems, Inc. Flexible stent
US7780700B2 (en) 2003-02-04 2010-08-24 ev3 Endovascular, Inc Patent foramen ovale closure system
WO2004075789A2 (fr) 2003-02-26 2004-09-10 Cook Incorporated Prothese conçue pour se poser sous imagerie externe
JP4691017B2 (ja) 2003-03-18 2011-06-01 セント ジュード メディカル インコーポレイテッド 体組織のリモデリング方法および装置
US7357818B2 (en) 2003-03-26 2008-04-15 Boston Scientific Scimed, Inc. Self-retaining stent
US20050107871A1 (en) 2003-03-30 2005-05-19 Fidel Realyvasquez Apparatus and methods for valve repair
US20050131523A1 (en) 2003-04-02 2005-06-16 Mehran Bashiri Detachable and retrievable stent assembly
US7159593B2 (en) 2003-04-17 2007-01-09 3F Therapeutics, Inc. Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation
US7530995B2 (en) 2003-04-17 2009-05-12 3F Therapeutics, Inc. Device for reduction of pressure effects of cardiac tricuspid valve regurgitation
US8221492B2 (en) 2003-04-24 2012-07-17 Cook Medical Technologies Artificial valve prosthesis with improved flow dynamics
US8267981B2 (en) 2003-06-10 2012-09-18 Depuy Mitek, Inc. Suture anchor with improved drive head
US7316706B2 (en) 2003-06-20 2008-01-08 Medtronic Vascular, Inc. Tensioning device, system, and method for treating mitral valve regurgitation
WO2004112652A2 (fr) 2003-06-20 2004-12-29 Medtronic Vascular, Inc. Dispositif, systeme et procede permettant de contracter un tissu dans le corps d'un mammifere
EP1648346A4 (fr) 2003-06-20 2006-10-18 Medtronic Vascular Inc Système pour réduire un espace annulaire d'une valvule prothètique
WO2005002424A2 (fr) 2003-07-02 2005-01-13 Flexcor, Inc. Anneaux d'annuloplastie et methodes de reparation de valvules cardiaques
DE602004024199D1 (de) 2003-07-02 2009-12-31 Cook Critical Care Inc Zentralvenenkatheter
US7201772B2 (en) 2003-07-08 2007-04-10 Ventor Technologies, Ltd. Fluid flow prosthetic device
US8480706B2 (en) 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US20050016560A1 (en) 2003-07-21 2005-01-27 Dee Voughlohn Unique hair-styling system and method
US7371244B2 (en) 2003-08-25 2008-05-13 Ethicon, Inc. Deployment apparatus for suture anchoring device
US20050049692A1 (en) 2003-09-02 2005-03-03 Numamoto Michael J. Medical device for reduction of pressure effects of cardiac tricuspid valve regurgitation
US20050059997A1 (en) 2003-09-17 2005-03-17 Bauman Ann M. Circular stapler buttress
US20050075717A1 (en) 2003-10-06 2005-04-07 Nguyen Tuoc Tan Minimally invasive valve replacement system
US20060259137A1 (en) 2003-10-06 2006-11-16 Jason Artof Minimally invasive valve replacement system
EP1682215B1 (fr) 2003-10-24 2008-12-24 Cardiac Pacemakers, Inc. Systeme de fixation de derivation myocardique
US20050090827A1 (en) 2003-10-28 2005-04-28 Tewodros Gedebou Comprehensive tissue attachment system
US7056286B2 (en) 2003-11-12 2006-06-06 Adrian Ravenscroft Medical device anchor and delivery system
US7655040B2 (en) 2003-11-12 2010-02-02 Medtronic Vascular, Inc. Cardiac valve annulus reduction system
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US20050177228A1 (en) 2003-12-16 2005-08-11 Solem Jan O. Device for changing the shape of the mitral annulus
US20050273138A1 (en) 2003-12-19 2005-12-08 Guided Delivery Systems, Inc. Devices and methods for anchoring tissue
US7258697B1 (en) 2003-12-22 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent with anchors to prevent vulnerable plaque rupture during deployment
US9005273B2 (en) 2003-12-23 2015-04-14 Sadra Medical, Inc. Assessing the location and performance of replacement heart valves
US8951299B2 (en) 2003-12-23 2015-02-10 Sadra Medical, Inc. Medical devices and delivery systems for delivering medical devices
US8840663B2 (en) 2003-12-23 2014-09-23 Sadra Medical, Inc. Repositionable heart valve method
US7824443B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Medical implant delivery and deployment tool
CN101947146B (zh) 2003-12-23 2014-08-06 萨德拉医学公司 可再定位的心脏瓣膜
US7431726B2 (en) 2003-12-23 2008-10-07 Mitralign, Inc. Tissue fastening systems and methods utilizing magnetic guidance
US7329279B2 (en) 2003-12-23 2008-02-12 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8182528B2 (en) 2003-12-23 2012-05-22 Sadra Medical, Inc. Locking heart valve anchor
US7390332B2 (en) * 2004-02-24 2008-06-24 Depuy Mitek, Inc. Methods and devices for repairing tissue
US20070208389A1 (en) 2004-02-25 2007-09-06 Amundson David C Coronary Sinus Locater Method and Apparatus for Biventricular Pacing
ITTO20040135A1 (it) 2004-03-03 2004-06-03 Sorin Biomedica Cardio Spa Protesi valvolare cardiaca
SE0400546D0 (sv) 2004-03-05 2004-03-05 Dan Lundgren Rörformigt benförankringselement
US20050203606A1 (en) 2004-03-09 2005-09-15 Vancamp Daniel H. Stent system for preventing restenosis
JP2007535342A (ja) 2004-03-11 2007-12-06 パーキュテイニアス カルディオバスキュラー ソリューションズ ピー・ティー・ワイ リミテッド 経皮的人工心臓弁
WO2005087139A1 (fr) 2004-03-15 2005-09-22 Baker Medical Research Institute Traitement d'une defaillance valvulaire
NL1025830C2 (nl) 2004-03-26 2005-02-22 Eric Berreklouw Samenstel omvattende een ring voor bevestiging in een door lichaamsweefsel omgeven doorgang alsmede een applicator voor het in de doorgang plaatsen van de ring.
US20050228388A1 (en) 2004-03-30 2005-10-13 Darrel Brodke Double lead bone screw
US7758491B2 (en) 2004-04-05 2010-07-20 Genesee Biomedical, Inc. Method and apparatus for the surgical treatment of congestive heart failure
US7374573B2 (en) 2004-05-03 2008-05-20 Shlomo Gabbay System and method for improving ventricular function
US7556645B2 (en) 2004-05-05 2009-07-07 Direct Flow Medical, Inc. Translumenally implantable heart valve with formed in place support
US7390329B2 (en) 2004-05-07 2008-06-24 Usgi Medical, Inc. Methods for grasping and cinching tissue anchors
US20060122692A1 (en) 2004-05-10 2006-06-08 Ran Gilad Stent valve and method of using same
US20050256532A1 (en) 2004-05-12 2005-11-17 Asha Nayak Cardiovascular defect patch device and method
US8617234B2 (en) 2004-05-25 2013-12-31 Covidien Lp Flexible vascular occluding device
US7276078B2 (en) 2004-06-30 2007-10-02 Edwards Lifesciences Pvt Paravalvular leak detection, sealing, and prevention
US7597703B2 (en) 2004-09-07 2009-10-06 Medtronic Vascular, Inc. Mechanically expandable occluder
US20090118776A1 (en) 2004-09-24 2009-05-07 Biomec, Inc. Tissue anchors
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
AU2005290341B2 (en) 2004-09-28 2012-01-19 Surgical Solutions Llc Suture anchor
US20070083168A1 (en) 2004-09-30 2007-04-12 Whiting James S Transmembrane access systems and methods
US20060106420A1 (en) 2004-11-12 2006-05-18 Medtronic Vascular, Inc. Patch for treating a septal defect
US7720550B2 (en) 2004-12-03 2010-05-18 Medtronic, Inc. High impedance active fixation electrode of an electrical medical lead
WO2009053952A2 (fr) 2007-10-26 2009-04-30 Mednua Limited Dispositif médical destiné à être utilisé dans le traitement d'une valvule
CA2590156A1 (fr) 2004-12-15 2006-06-22 Cook Urological Incorporated Dispositifs de manipulation radio-opaques
EP1841383A1 (fr) 2004-12-15 2007-10-10 Mednua Limited Dispositif medical pouvant etre utilise dans le traitement d'une valvule
WO2006086434A1 (fr) 2005-02-07 2006-08-17 Evalve, Inc. Procedes, systemes et dispositifs pour reparer une valvule cardiaque
ATE555714T1 (de) 2005-02-08 2012-05-15 Koninkl Philips Electronics Nv System zur perkutanen glosssoplastik
US9089323B2 (en) 2005-02-22 2015-07-28 P Tech, Llc Device and method for securing body tissue
US8608797B2 (en) 2005-03-17 2013-12-17 Valtech Cardio Ltd. Mitral valve treatment techniques
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
US8864823B2 (en) 2005-03-25 2014-10-21 StJude Medical, Cardiology Division, Inc. Methods and apparatus for controlling the internal circumference of an anatomic orifice or lumen
JP5149150B2 (ja) 2005-03-25 2013-02-20 ミトラル・ソリューションズ・インコーポレイテッド 解剖学的なオリフィス又は内腔の内周を制御するための方法及び装置
US20060259135A1 (en) 2005-04-20 2006-11-16 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
SE531468C2 (sv) 2005-04-21 2009-04-14 Edwards Lifesciences Ag En anordning för styrning av blodflöde
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US7500989B2 (en) 2005-06-03 2009-03-10 Edwards Lifesciences Corp. Devices and methods for percutaneous repair of the mitral valve via the coronary sinus
US20070016288A1 (en) 2005-07-13 2007-01-18 Gurskis Donnell W Two-piece percutaneous prosthetic heart valves and methods for making and using them
DE102006017873A1 (de) 2005-07-14 2007-01-25 Qualimed Innovative Medizinprodukte Gmbh Temporärer Stent
EP1903991B1 (fr) 2005-07-15 2009-09-09 The Cleveland Clinic Foundation Appareil de remodelage de l'anneau d'une valve cardiaque
US7875056B2 (en) 2005-07-22 2011-01-25 Anpa Medical, Inc. Wedge operated retainer device and methods
US20070060895A1 (en) 2005-08-24 2007-03-15 Sibbitt Wilmer L Jr Vascular closure methods and apparatuses
US9492277B2 (en) 2005-08-30 2016-11-15 Mayo Foundation For Medical Education And Research Soft body tissue remodeling methods and apparatus
US20070078297A1 (en) 2005-08-31 2007-04-05 Medtronic Vascular, Inc. Device for Treating Mitral Valve Regurgitation
US7846179B2 (en) 2005-09-01 2010-12-07 Ovalis, Inc. Suture-based systems and methods for treating septal defects
US8968379B2 (en) 2005-09-02 2015-03-03 Medtronic Vascular, Inc. Stent delivery system with multiple evenly spaced pullwires
US20070060989A1 (en) 2005-09-07 2007-03-15 Deem Mark E Apparatus and method for disrupting subcutaneous structures
WO2007030823A2 (fr) 2005-09-09 2007-03-15 Edwards Lifesciences Corporation Dispositif et methode pour une reformation d'un anneau de valve de mitrale
US20080190989A1 (en) 2005-10-03 2008-08-14 Crews Samuel T Endoscopic plication device and method
US8092525B2 (en) 2005-10-26 2012-01-10 Cardiosolutions, Inc. Heart valve implant
US7785366B2 (en) 2005-10-26 2010-08-31 Maurer Christopher W Mitral spacer
US8449606B2 (en) 2005-10-26 2013-05-28 Cardiosolutions, Inc. Balloon mitral spacer
US8778017B2 (en) 2005-10-26 2014-07-15 Cardiosolutions, Inc. Safety for mitral valve implant
US8852270B2 (en) 2007-11-15 2014-10-07 Cardiosolutions, Inc. Implant delivery system and method
US8216302B2 (en) 2005-10-26 2012-07-10 Cardiosolutions, Inc. Implant delivery and deployment system and method
US9259317B2 (en) 2008-06-13 2016-02-16 Cardiosolutions, Inc. System and method for implanting a heart implant
US8343204B2 (en) 2005-10-31 2013-01-01 Cook Medical Technologies Llc Composite stent graft
EP1954198A1 (fr) 2005-11-15 2008-08-13 Aoi Medical, Inc. Bouton de fermeture arterielle
US20070118151A1 (en) 2005-11-21 2007-05-24 The Brigham And Women's Hospital, Inc. Percutaneous cardiac valve repair with adjustable artificial chordae
FR2894131B1 (fr) 2005-12-02 2008-12-05 Perouse Soc Par Actions Simpli Dispositif de traitement d'un vaisseau sanguin, et necessaire de traitement associe.
US8197441B2 (en) 2005-12-06 2012-06-12 Abbott Cardiovascular Systems Inc. Catheter mounted automatic vessel occlusion and fluid dispersion devices
US7901454B2 (en) 2005-12-15 2011-03-08 The Cleveland Clinic Foundation Apparatus and method for treating a regurgitant valve
US9125742B2 (en) 2005-12-15 2015-09-08 Georgia Tech Research Foundation Papillary muscle position control devices, systems, and methods
WO2007072399A1 (fr) 2005-12-19 2007-06-28 Robert William Mayo Frater Prothese pour annuloplastie
CA2634358A1 (fr) 2005-12-22 2007-06-28 Symetis Sa Valves stents pour remplacer des valves, et methodes et systemes de chirurgie associes
US20070168013A1 (en) 2006-01-19 2007-07-19 Myles Douglas Vascular graft and deployment system
US7628797B2 (en) 2006-01-31 2009-12-08 Edwards Lifesciences Corporation System, apparatus, and method for fastening tissue
WO2008029296A2 (fr) 2006-02-16 2008-03-13 Endocor Pte Ltd. Remplacement d'une valvule cardiaque en une chirurgie mini-invasive
US20070203391A1 (en) 2006-02-24 2007-08-30 Medtronic Vascular, Inc. System for Treating Mitral Valve Regurgitation
US8801777B2 (en) 2007-04-18 2014-08-12 David Elmaleh Intravascular device with netting system
ITMI20060410A1 (it) 2006-03-07 2007-09-08 Ethicon Endo Surgery Inc Dispositivo anastomotico
US20070219558A1 (en) 2006-03-15 2007-09-20 Allen Deutsch Method and apparatus for arthroscopic surgery using suture anchors
US7815652B2 (en) 2006-03-21 2010-10-19 Ethicon Endo-Surgery, Inc. Surgical fastener and instrument
US20090254103A1 (en) 2006-03-29 2009-10-08 Deutsch Harvey L Method and device for cavity obliteration
SG177123A1 (en) 2006-03-31 2012-01-30 Univ Nanyang Tech A tissue retractor, tissue retractor kit and method of use thereof
US7442207B2 (en) 2006-04-21 2008-10-28 Medtronic Vascular, Inc. Device, system, and method for treating cardiac valve regurgitation
JP2009535128A (ja) 2006-04-29 2009-10-01 アーバー・サージカル・テクノロジーズ・インコーポレイテッド 複数部品の人工心臓弁アセンブリと、それを届けるための装置及び方法
US9101338B2 (en) 2006-05-03 2015-08-11 Mayo Foundation For Medical Education And Research Soft body tissue remodeling methods and apparatus
CA2677968C (fr) 2006-05-15 2014-07-08 Enovacor Aps Systeme et procede de modification de la geometrie du coeur
US8932348B2 (en) 2006-05-18 2015-01-13 Edwards Lifesciences Corporation Device and method for improving heart valve function
JP2009538215A (ja) 2006-05-25 2009-11-05 ミトラリグン・インコーポレーテッド 外科用緊張部材のためのロッカーおよび外科用緊張部材を固定するためのその使用方法
CN102283721B (zh) 2006-06-01 2015-08-26 爱德华兹生命科学公司 用于改善心瓣膜功能的人工***物
US7934506B2 (en) 2006-06-21 2011-05-03 Koninklijke Philips Electronics N.V. System and method for temporary tongue suspension
WO2008010905A2 (fr) 2006-06-30 2008-01-24 Cvdevices, Llc Accès intravasculaire percutané au tissu cardiaque
US20080077231A1 (en) 2006-07-06 2008-03-27 Prescient Medical, Inc. Expandable vascular endoluminal prostheses
US7527185B2 (en) 2006-07-12 2009-05-05 Niti Surgical Solutions Ltd. Compression anastomosis ring assembly and applicator for use therewith
US20080097595A1 (en) 2006-08-22 2008-04-24 Shlomo Gabbay Intraventricular cardiac prosthesis
US7771467B2 (en) 2006-11-03 2010-08-10 The Cleveland Clinic Foundation Apparatus for repairing the function of a native aortic valve
CA2671966A1 (fr) 2006-12-05 2008-06-12 Valtech Cardio, Ltd. Placement d'anneau segmente
US8236045B2 (en) 2006-12-22 2012-08-07 Edwards Lifesciences Corporation Implantable prosthetic valve assembly and method of making the same
WO2008097589A1 (fr) 2007-02-05 2008-08-14 Boston Scientific Limited Valve percutanée, système et procédé
US20080208327A1 (en) 2007-02-27 2008-08-28 Rowe Stanton J Method and apparatus for replacing a prosthetic valve
US8758406B2 (en) 2007-03-05 2014-06-24 Tomier, Inc. Tack anchor systems, bone anchor systems, and methods of use
US8137381B2 (en) 2007-04-25 2012-03-20 Arthrocare Corporation Knotless suture anchor having discrete polymer components and related methods
US8480730B2 (en) 2007-05-14 2013-07-09 Cardiosolutions, Inc. Solid construct mitral spacer
US7991484B1 (en) 2007-05-15 2011-08-02 Pacesetter, Inc. Active fixation medical lead and related method and system
WO2008147875A1 (fr) 2007-05-31 2008-12-04 Wilson-Cook Medical, Inc. Arrêt de suture
EP2157916A2 (fr) 2007-06-04 2010-03-03 Mor Research Applications Ltd. Augmentation de feuillet de valvule cardiaque
US9814611B2 (en) 2007-07-31 2017-11-14 Edwards Lifesciences Cardiaq Llc Actively controllable stent, stent graft, heart valve and method of controlling same
US8025495B2 (en) 2007-08-27 2011-09-27 Cook Medical Technologies Llc Apparatus and method for making a spider occlusion device
DE102007043830A1 (de) 2007-09-13 2009-04-02 Lozonschi, Lucian, Madison Herzklappenstent
EP2203216A1 (fr) 2007-09-20 2010-07-07 Nanostim, Inc. Stimulateur cardiaque sans fil avec capacité de fixation secondaire
US20090082847A1 (en) 2007-09-26 2009-03-26 Boston Scientific Corporation System and method of securing stent barbs
US8454686B2 (en) 2007-09-28 2013-06-04 St. Jude Medical, Inc. Two-stage collapsible/expandable prosthetic heart valves and anchoring systems
US8784481B2 (en) 2007-09-28 2014-07-22 St. Jude Medical, Inc. Collapsible/expandable prosthetic heart valves with native calcified leaflet retention features
US20090084386A1 (en) 2007-10-01 2009-04-02 Mcclellan Annette M L Tubal ligation
JP2010540190A (ja) 2007-10-04 2010-12-24 トリバスキュラー・インコーポレイテッド 低プロファイル経皮的送達のためのモジュラー式血管グラフト
US9414842B2 (en) 2007-10-12 2016-08-16 St. Jude Medical, Cardiology Division, Inc. Multi-component vascular device
WO2009052188A1 (fr) 2007-10-15 2009-04-23 Edwards Lifesciences Corporation Valvule cardiaque transcathéter pourvue de microdispositifs d'ancrage
US8236013B2 (en) 2007-10-19 2012-08-07 Boston Scientific Scimed, Inc. Apparatus for placing medical implants
US8821366B2 (en) 2007-10-24 2014-09-02 Circulite, Inc. Transseptal cannula, tip, delivery system, and method
US8597347B2 (en) 2007-11-15 2013-12-03 Cardiosolutions, Inc. Heart regurgitation method and apparatus
US20100298930A1 (en) 2007-12-02 2010-11-25 Boris Orlov Access to the left atrium and reduction of mitral valve leaflet mobility
US9131928B2 (en) 2007-12-20 2015-09-15 Mor Research Applications Ltd. Elongated body for deployment in a heart
EP3449875A1 (fr) 2008-01-24 2019-03-06 Medtronic, Inc. Stents pour des valvules cardiaques prothétiques
EP2244661B1 (fr) 2008-02-11 2012-03-28 Corassist Cardiovascular Ltd. Dispositifs d'assistance de la fonction ventriculair
DE102008012113A1 (de) 2008-03-02 2009-09-03 Transcatheter Technologies Gmbh Stent, welcher vom expandierten Zustand erneut im Durchmesser kontrolliert verringerbar ist
US9445804B2 (en) 2008-04-01 2016-09-20 The Lonnie And Shannon Paulos Trust (As Amended And Restated) Suture anchoring assemblies and methods of use
US8262725B2 (en) 2008-04-16 2012-09-11 Cardiovascular Technologies, Llc Transvalvular intraannular band for valve repair
US20100121435A1 (en) 2008-04-16 2010-05-13 Cardiovascular Technologies, Llc Percutaneous transvalvular intrannular band for mitral valve repair
WO2009129481A1 (fr) 2008-04-18 2009-10-22 Cook Incorporated Prothèse de vaisseau ramifié
FR2930137B1 (fr) 2008-04-18 2010-04-23 Corevalve Inc Materiel de traitement d'une valve cardiaque, en particulier d'une valve mitrale.
US20090276040A1 (en) 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
EP2291123A2 (fr) 2008-05-12 2011-03-09 John T.M. Wright Dispositif et procédé pour le traitement chirurgical d'une régurgitation mitrale ischémique
US20090287304A1 (en) 2008-05-13 2009-11-19 Kardium Inc. Medical Device for Constricting Tissue or a Bodily Orifice, for example a mitral valve
JP5536764B2 (ja) 2008-06-04 2014-07-02 ゴア エンタープライズ ホールディングス，インコーポレイティド 制御展開可能な医療デバイス及びその製造方法
US8591460B2 (en) 2008-06-13 2013-11-26 Cardiosolutions, Inc. Steerable catheter and dilator and system and method for implanting a heart implant
CA2728078A1 (fr) 2008-06-16 2010-01-14 Valtech Cardio, Ltd. Dispositifs d'annuloplastie et procedes de mise en place de ceux-ci
US8323335B2 (en) 2008-06-20 2012-12-04 Edwards Lifesciences Corporation Retaining mechanisms for prosthetic valves and methods for using
AU2009271574B2 (en) 2008-07-15 2015-05-21 St. Jude Medical, Inc. Axially anchoring collapsible and re-expandable prosthetic heart valves for various disease states
AU2009274131B2 (en) 2008-07-21 2015-06-04 Jennifer K. White Repositionable endoluminal support structure and its applications
US20100023118A1 (en) 2008-07-24 2010-01-28 Edwards Lifesciences Corporation Method and apparatus for repairing or replacing chordae tendinae
US7776743B2 (en) 2008-07-30 2010-08-17 Tel Epion Inc. Method of forming semiconductor devices containing metal cap layers
US8777990B2 (en) 2008-09-08 2014-07-15 Howmedica Osteonics Corp. Knotless suture anchor for soft tissue repair and method of use
JP2012505048A (ja) 2008-10-10 2012-03-01 ガイデッド デリバリー システムズ， インコーポレイテッド 終端デバイスおよび関連方法
WO2010071494A1 (fr) 2008-12-19 2010-06-24 St.Jude Medical Ab Dérivation implantable médicale et procédé garantissant sa fixation correcte et sûre à un organe
US8715342B2 (en) 2009-05-07 2014-05-06 Valtech Cardio, Ltd. Annuloplasty ring with intra-ring anchoring
CN102341063B (zh) 2008-12-22 2015-11-25 瓦尔泰克卡迪欧有限公司 可调瓣环成形装置及其调节机构
US8911494B2 (en) 2009-05-04 2014-12-16 Valtech Cardio, Ltd. Deployment techniques for annuloplasty ring
US8147542B2 (en) 2008-12-22 2012-04-03 Valtech Cardio, Ltd. Adjustable repair chords and spool mechanism therefor
US8241351B2 (en) 2008-12-22 2012-08-14 Valtech Cardio, Ltd. Adjustable partial annuloplasty ring and mechanism therefor
US8808368B2 (en) 2008-12-22 2014-08-19 Valtech Cardio, Ltd. Implantation of repair chords in the heart
US20110011917A1 (en) 2008-12-31 2011-01-20 Hansen Medical, Inc. Methods, devices, and kits for treating valve prolapse
EP2381852A4 (fr) 2009-01-21 2014-06-11 Tendyne Medical Inc Ancrage apical des muscles papillaires en vue d'une réduction du ventricule gauche
US8108054B2 (en) 2009-02-04 2012-01-31 Pacesetter, Inc. Active fixation implantable medical lead configured to indicate via fluoroscopy embedment of helical anchor in cardiac tissue
US8353956B2 (en) 2009-02-17 2013-01-15 Valtech Cardio, Ltd. Actively-engageable movement-restriction mechanism for use with an annuloplasty structure
US20100217382A1 (en) 2009-02-25 2010-08-26 Edwards Lifesciences Mitral valve replacement with atrial anchoring
EP2400924B1 (fr) 2009-02-27 2017-06-28 St. Jude Medical, Inc. Valvules cardiaque prothétique
WO2010099437A1 (fr) 2009-02-27 2010-09-02 Silk Road Medical, Inc. Dispositif de pince destiné à la fermeture de vaisseaux
US9980818B2 (en) 2009-03-31 2018-05-29 Edwards Lifesciences Corporation Prosthetic heart valve system with positioning markers
CA2758509C (fr) 2009-04-15 2018-02-20 Microvention, Inc. Systeme de mise en place d'implant
EP2810620B1 (fr) 2009-04-15 2022-09-14 Edwards Lifesciences CardiAQ LLC Implant vasculaire et système de distribution
US8292154B2 (en) 2009-04-16 2012-10-23 Tyco Healthcare Group Lp Surgical apparatus for applying tissue fasteners
US20100286628A1 (en) 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
US8523881B2 (en) 2010-07-26 2013-09-03 Valtech Cardio, Ltd. Multiple anchor delivery tool
US20110238112A1 (en) 2009-05-29 2011-09-29 Kim Andrew C Suture anchor
US8409269B2 (en) 2009-12-21 2013-04-02 Covidien Lp Procedures for vascular occlusion
US8828040B2 (en) 2009-07-07 2014-09-09 Thomas G. Goff Device and methods for delivery and transfer of temporary radiopaque element
US20110077733A1 (en) 2009-09-25 2011-03-31 Edwards Lifesciences Corporation Leaflet contacting apparatus and method
WO2011041571A2 (fr) 2009-10-01 2011-04-07 Kardium Inc. Dispositif médical, kit et procédé de construction de tissu ou d'orifice corporel, par exemple de valvule mitrale
WO2011044486A1 (fr) 2009-10-09 2011-04-14 Boston Scientific Scimed, Inc. Dérivation gastrique pour le traitement de l'obésité
US20110093002A1 (en) 2009-10-20 2011-04-21 Wilson-Cook Medical Inc. Stent-within-stent arrangements
US20110092993A1 (en) 2009-10-20 2011-04-21 Moises Jacobs Tissue approximating device
US20110098732A1 (en) 2009-10-27 2011-04-28 Moises Jacobs Visceral tissue approximating method and device
US9180007B2 (en) 2009-10-29 2015-11-10 Valtech Cardio, Ltd. Apparatus and method for guide-wire based advancement of an adjustable implant
US8940042B2 (en) 2009-10-29 2015-01-27 Valtech Cardio, Ltd. Apparatus for guide-wire based advancement of a rotation assembly
US8277502B2 (en) 2009-10-29 2012-10-02 Valtech Cardio, Ltd. Tissue anchor for annuloplasty device
US9011520B2 (en) 2009-10-29 2015-04-21 Valtech Cardio, Ltd. Tissue anchor for annuloplasty device
US8812134B2 (en) 2009-11-12 2014-08-19 Cardiac Pacemakers Inc. Helix fixation mechanism
WO2011065881A1 (fr) 2009-11-30 2011-06-03 St. Jude Medical Ab Conducteur implantable médical avec détection de fixation
US8449599B2 (en) 2009-12-04 2013-05-28 Edwards Lifesciences Corporation Prosthetic valve for replacing mitral valve
WO2011072084A2 (fr) 2009-12-08 2011-06-16 Avalon Medical Ltd. Dispositif et système de remplacement de valvule mitrale transcathéter
US8870950B2 (en) 2009-12-08 2014-10-28 Mitral Tech Ltd. Rotation-based anchoring of an implant
US8475525B2 (en) 2010-01-22 2013-07-02 4Tech Inc. Tricuspid valve repair using tension
US8961596B2 (en) 2010-01-22 2015-02-24 4Tech Inc. Method and apparatus for tricuspid valve repair using tension
US9307980B2 (en) 2010-01-22 2016-04-12 4Tech Inc. Tricuspid valve repair using tension
US9107749B2 (en) 2010-02-03 2015-08-18 Edwards Lifesciences Corporation Methods for treating a heart
DE102010008360A1 (de) 2010-02-17 2011-09-29 Transcatheter Technologies Gmbh Medizinisches Implantat, in welchem beim Crimpen bzw. Falten Lücken verbleiben, Verfahren und Einrichtung zum Verbringen
US9226826B2 (en) 2010-02-24 2016-01-05 Medtronic, Inc. Transcatheter valve structure and methods for valve delivery
WO2011111047A2 (fr) 2010-03-10 2011-09-15 Mitraltech Ltd. Valvule mitrale prothétique avec ancrages de tissus
ES2365317B1 (es) 2010-03-19 2012-08-03 Xavier Ruyra Baliarda Banda protésica, en particular para la reparación de una válvula mitral.
US9326870B2 (en) 2010-04-23 2016-05-03 Medtronic Vascular, Inc. Biodegradable stent having non-biodegradable end portions and mechanisms for increased stent hoop strength
US9795482B2 (en) 2010-04-27 2017-10-24 Medtronic, Inc. Prosthetic heart valve devices and methods of valve repair
JP5827991B2 (ja) 2010-05-10 2015-12-02 エイチエルティー， インコーポレイテッド ステントレス支持構造
US8790394B2 (en) 2010-05-24 2014-07-29 Valtech Cardio, Ltd. Adjustable artificial chordeae tendineae with suture loops
WO2011151745A1 (fr) 2010-06-03 2011-12-08 Koninklijke Philips Electronics N.V. Système permettant de soulager la tension s'exerçant sur un implant utilisé en cas de glossoplastie
US20130030522A1 (en) 2010-06-16 2013-01-31 Rowe Stanton J Devices and methods for heart treatments
US20120130421A1 (en) 2010-06-18 2012-05-24 The Curators Of The University Of Missouri Ratcheting staple for surgical applications
WO2011162287A1 (fr) 2010-06-22 2011-12-29 オリンパスメディカルシステムズ株式会社 Procédé de production de pinces de tissu, et pince de tissu
WO2012012209A2 (fr) 2010-07-19 2012-01-26 Sukhjit Gill Système de stabilisation de sonde-guide
US8992604B2 (en) 2010-07-21 2015-03-31 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9132009B2 (en) 2010-07-21 2015-09-15 Mitraltech Ltd. Guide wires with commissural anchors to advance a prosthetic valve
EP2595569A4 (fr) 2010-07-23 2016-02-24 Edwards Lifesciences Corp Mécanismes de rétention pour prothèses valvulaires
WO2012019052A2 (fr) 2010-08-04 2012-02-09 Micardia Corporation Réparation des valvules cardiaques par cathétérisme percutané
US10105224B2 (en) 2010-09-01 2018-10-23 Mvalve Technologies Ltd. Cardiac valve support structure
US8940002B2 (en) 2010-09-30 2015-01-27 Kardium Inc. Tissue anchor system
AU2011332225B2 (en) 2010-11-23 2016-05-26 Cc Innovation Surgical implant
EP2478868A1 (fr) 2011-01-25 2012-07-25 The Provost, Fellows, Foundation Scholars, and the other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Dispositif servant d'implant
US9445898B2 (en) 2011-03-01 2016-09-20 Medtronic Ventor Technologies Ltd. Mitral valve repair
EP2688516B1 (fr) 2011-03-21 2022-08-17 Cephea Valve Technologies, Inc. Appareil pour valvule à disques
US9072511B2 (en) 2011-03-25 2015-07-07 Kardium Inc. Medical kit for constricting tissue or a bodily orifice, for example, a mitral valve
US8721588B2 (en) 2011-04-15 2014-05-13 DePuy Synthes Products, LLC Noncircular inner lumen guiding catheter with assisted variable support
US20120296349A1 (en) 2011-05-17 2012-11-22 Boston Scientific Scimed, Inc. Percutaneous Mitral Annulus Mini-Plication
US9289282B2 (en) 2011-05-31 2016-03-22 Edwards Lifesciences Corporation System and method for treating valve insufficiency or vessel dilatation
EP2734157B1 (fr) 2011-07-21 2018-09-05 4Tech Inc. Appareil pour la réparation d'une valvule tricuspide en utilisant une tension
US8852272B2 (en) 2011-08-05 2014-10-07 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US20140324164A1 (en) 2011-08-05 2014-10-30 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9480559B2 (en) 2011-08-11 2016-11-01 Tendyne Holdings, Inc. Prosthetic valves and related inventions
US20140194681A1 (en) * 2011-08-25 2014-07-10 Mis Solutions, Inc. Apparatus and method for intra-abdominally moving a first internal organ to a position away from a second internal organ and then holding the first internal organ in the position without manual input
US8764798B2 (en) 2011-10-03 2014-07-01 Smith & Nephew, Inc. Knotless suture anchor
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9827093B2 (en) 2011-10-21 2017-11-28 Edwards Lifesciences Cardiaq Llc Actively controllable stent, stent graft, heart valve and method of controlling same
US8858623B2 (en) 2011-11-04 2014-10-14 Valtech Cardio, Ltd. Implant having multiple rotational assemblies
US20140350660A1 (en) 2011-12-01 2014-11-27 Graeme Cocks Endoluminal Prosthesis
JP6153938B2 (ja) 2011-12-12 2017-06-28 デイヴィッド・アロン 心臓弁修復デバイス
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
US9078747B2 (en) 2011-12-21 2015-07-14 Edwards Lifesciences Corporation Anchoring device for replacing or repairing a heart valve
ES2785667T3 (es) 2012-01-31 2020-10-07 Mitral Valve Tech Sarl Dispositivos y sistemas de sujeción de válvula mitral
US20150094802A1 (en) 2012-02-28 2015-04-02 Mvalve Technologies Ltd. Single-ring cardiac valve support
US8961594B2 (en) 2012-05-31 2015-02-24 4Tech Inc. Heart valve repair system
DE102012010798A1 (de) 2012-06-01 2013-12-05 Universität Duisburg-Essen Implantierbare Vorrichtung zur Verbesserung oder Behebung einer Herzklappeninsuffizienz
US9504571B2 (en) 2012-06-07 2016-11-29 Edwards Lifesciences Corporation Systems for implanting annuloplasty rings with microanchors
US9259315B2 (en) 2012-07-12 2016-02-16 Boston Scientific Scimed, Inc. Low profile heart valve delivery system and method
WO2014022124A1 (fr) 2012-07-28 2014-02-06 Tendyne Holdings, Inc. Conceptions multi-composantes améliorées pour dispositif de récupération de valve cardiaque, structures d'étanchéité et ensemble stent
US9550058B2 (en) 2012-08-27 2017-01-24 Cardiac Pacemakers, Inc. Compound-shaped stylet for torque transmission
EP3730084A1 (fr) 2012-10-23 2020-10-28 Valtech Cardio, Ltd. Fonction de direction contrôlée pour outil de pose d'implant
US9023099B2 (en) 2012-10-31 2015-05-05 Medtronic Vascular Galway Limited Prosthetic mitral valve and delivery method
US8628571B1 (en) 2012-11-13 2014-01-14 Mitraltech Ltd. Percutaneously-deliverable mechanical valve
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9730793B2 (en) 2012-12-06 2017-08-15 Valtech Cardio, Ltd. Techniques for guide-wire based advancement of a tool
CN105007832B (zh) 2013-01-09 2018-01-23 4科技有限公司 组织锚状物设备
WO2014115149A2 (fr) 2013-01-24 2014-07-31 Mitraltech Ltd. Valves prothétiques à ancrage ventriculaire
EP2961351B1 (fr) 2013-02-26 2018-11-28 Mitralign, Inc. Dispositif pour réparation percutanée de valve tricuspide
WO2014141239A1 (fr) 2013-03-14 2014-09-18 4Tech Inc. Endoprothèse ayant une interface de câble d'attache
CA2907185C (fr) 2013-03-15 2019-12-17 Hlt, Inc. Structure de valve prothetique au profil bas
US20140358224A1 (en) 2013-05-30 2014-12-04 Tendyne Holdlings, Inc. Six cell inner stent device for prosthetic mitral valves
CA2902169C (fr) 2013-06-25 2022-07-26 Michael Sutherland Reparation de valve percutanee par remise en forme et redimensionnement du ventricule droit
US20140379076A1 (en) 2013-06-25 2014-12-25 Tendyne Holdings, Inc. Halo Wire Fluid Seal Device for Prosthetic Mitral Valves
WO2015006575A1 (fr) 2013-07-10 2015-01-15 Medtronic Inc. Systèmes et procédés d'annuloplastie de valvule mitrale à bobine hélicoïdale
EP3030161A4 (fr) 2013-08-06 2017-03-22 LC Therapeutics, Inc. Cordon synthétique pour applications de réparation de valvules cardiaques
WO2015022710A1 (fr) 2013-08-14 2015-02-19 Sorin Group Italia S.R.L. Appareil et procédé de remplacement de cordage
US10117742B2 (en) 2013-09-12 2018-11-06 St. Jude Medical, Cardiology Division, Inc. Stent designs for prosthetic heart valves
US9248018B2 (en) 2013-09-27 2016-02-02 Surendra K. Chawla Valve repair device
US20150100116A1 (en) 2013-10-07 2015-04-09 Medizinische Universitat Wien Implant and method for improving coaptation of an atrioventricular valve
WO2015063580A2 (fr) 2013-10-30 2015-05-07 4Tech Inc. Système de tension à multiples points d'ancrage
US10022114B2 (en) 2013-10-30 2018-07-17 4Tech Inc. Percutaneous tether locking
US10052095B2 (en) 2013-10-30 2018-08-21 4Tech Inc. Multiple anchoring-point tension system
US9610162B2 (en) 2013-12-26 2017-04-04 Valtech Cardio, Ltd. Implantation of flexible implant
US9072604B1 (en) 2014-02-11 2015-07-07 Gilberto Melnick Modular transcatheter heart valve and implantation method
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
US20150250590A1 (en) 2014-03-10 2015-09-10 St. Jude Medical, Cardiology Division, Inc. Transapical mitral chordae replacement
EP3157607B1 (fr) 2014-06-19 2019-08-07 4Tech Inc. Serrage de tissu cardiaque
WO2016087934A1 (fr) 2014-12-02 2016-06-09 4Tech Inc. Ancrages de tissu excentrés

Also Published As

Publication number Publication date
US20160235533A1 (en) 2016-08-18
WO2015063580A2 (fr) 2015-05-07
WO2015063580A3 (fr) 2015-07-23
US10039643B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
US10052095B2 (en) Multiple anchoring-point tension system
US10039643B2 (en) Multiple anchoring-point tension system
US20180344311A1 (en) Percutaneous Tether Locking
US11497485B2 (en) Off-center tissue anchors
CN110755176B (zh) 用于在约束状态下在部署工具内递送的装置
JP7097351B2 (ja) インプラント
US9592122B2 (en) Annuloplasty ring with intra-ring anchoring
EP2427145B1 (fr) Système de déploiement d'anneau d'annuloplastie et outil de rotation sur fil
US20210015611A1 (en) Percutaneous implant retrieval system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160525

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 4TECH INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170103